Specific antifungal medication
Patent Information
- Application Number
- LAP270
- Authority / Receiving Office
- LA · LA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2011-01-30
- Filing Date
- 2012-01-30
- Publication Date
- 2025-09-26
AI Technical Summary
Current treatments for onychomycosis, caused by dermatophytes like Trichophyton, are inadequate due to limited penetration of topical antifungal agents into the nail and potential side effects of oral agents, particularly in elderly and diabetic patients.
Development of 2-(1H-pyrazol-1-yl)phenol derivatives with enhanced nail permeability, providing strong anti-ringworm activity and improved penetration into the nail, thus serving as effective anti-tinea unguium agents.
The 2-(1H-pyrazol-1-yl)phenol derivatives exhibit strong anti-fungal activity and high nail permeability, effectively treating onychomycosis without the side effects associated with long-term oral antifungal use, offering a preventive effect against recurrence and reinfection.
Abstract
Description
The present invention relates to novel 2-(1H-pyrazole-1-yl)phenol derivatives or pharmaceutically acceptable salts thereof that are suitable as anti-dermatophyte agents, and anti-dermatophyte agents containing these compounds as active ingredients. Mycoses are diseases caused by fungal infections in humans and animals. Representative mycoses in humans include candidiasis caused by Candida, cryptococcosis caused by Cryptococcus, aspergillosis caused by Aspergillus, zygomycosis caused by Zygomycetes, and dermatophytosis (ringworm) caused by Trichophyton (Pathogenic Fungi and Mycoses (Nanzando, Revised 2nd Edition), pp. 42-45; Non-Patent Literature 1). Dermatophytes are dermatophytes that can cause ringworm and possess the property of keratin-degrading ability. This ability allows them to invade the skin, nails, and hair and cause ringworm (Pathogenic Fungi and Mycosis (Nanzando, Revised 2nd Edition), pp. 184-187; Non-Patent Literature 2). Onychomycosis is a nail disease caused by dermatophytes, characterized by symptoms such as clouding, thickening, destruction, and deformation of the nail plate. Currently, it is estimated that one in ten Japanese people, or approximately 12 million people, suffer from this condition. It is a disease that is more common in the elderly, and there are concerns that the number of patients will increase further in the future. In addition, there are reports that people with diabetes are more susceptible to it, and it has been pointed out that it may cause serious complications. Currently in Japan, the only approved treatment method is oral antifungal medication (itraconazole and terbinafine). Topical antifungal agents, commonly used for skin fungal infections, cannot penetrate the keratin, interior, or nail bed of the nail, and therefore cannot be expected to be sufficiently effective. Furthermore, oral antifungal agents have been associated with drug interactions, liver damage, and side effects from long-term administration. Elderly individuals and diabetic patients, who have a high incidence of onychomycosis, often take multiple medications, making oral administration of antifungal drugs for the treatment of onychomycosis difficult in many cases (Br. J. of Dermatol., vol.139(4), p665, 1998; Non-patent Literature 3). Abroad, amorolfine and ciclopirox topical nail lacquer agents have been approved and used. However, their penetration into the nails is very low, and it is impossible to expect them to further penetrate and reach the nail matrix cells. Therefore, compared with oral medications, the effects are not sufficient. In recent years, antifungal agents and formulations aimed at improving nail penetration have been studied, but no antifungal agents or formulations with sufficient nail penetration for treatment have been found. As compounds having a 2-(1H-pyrazol-1-yl)phenol skeleton, 2-(3,5-dimethyl-1H-pyrazol-1-yl)phenol having methyl groups at the 3- and 5-positions of the pyrazole ring is known (Annual Report of Takeda Research Laboratories (1963) 22, p27; Non-Patent Document 4). These are aimed at inhibiting the growth of Mycobacterium tuberculosis in humans. Non-Patent Document 4 does not disclose 2-(1H-pyrazol-1-yl)phenol compounds other than 2-(3,5-dimethyl-1H-pyrazol-1-yl)phenol. In addition to 2-(3,5-dimethyl-1H-pyrazol-1-yl)phenol, compounds having a 2-(1H-pyrazol-1-yl)phenol skeleton such as 2-(1H-pyrazol-1-yl)phenol, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-1,4-benzenediol, and 2-(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl)-1,4-benzenediol are known. These are used in various chemical reactions, as raw materials for electroluminescent device compounds (Japanese Patent No. 4284169: Patent Document 1), and as light stabilizers (Spanish Published Patent Application No. 20158648: Patent Document 2), etc. Also, in WO2003 / 005999 (Patent Document 3), there is a disclosure of 2-(5-amino-3-tert-butyl-1H-pyrazol-1-yl)-5-methylphenol. These prior art documents do not suggest or disclose the anti-dermatophyte activity of compounds having a 2-(1H-pyrazol-1-yl)phenol skeleton. Japanese Patent No. 4284169 Spanish Published Patent Application No. 20158648 WO2003 / 005999 Pathogenic fungi and mycoses (Nanzando, revised 2nd edition), p42-45 Pathogenic fungi and mycoses (Nanzando, revised 2nd edition), p184-187 Br. J. of Dermatol., vol.139(4), p665, 1998 Takeda Research Institute Annual Report (1963) 22, p27 As described above, there is a strong need for the development of compounds that not only have antifungal activity but also high permeability to the nail as topical treatments for onychomycosis. Therefore, the object of the present invention is to provide a compound that has antifungal activity and is also permeable to the nail. The inventors have discovered that compounds having a 2-(1H-pyrazole-1-yl)phenol skeleton represented by the following formula (I) or (II), or salts thereof, possess unexpectedly strong anti-dermatophyte activity and high nail permeability. Based on these findings, the inventors have completed the present invention. In other words, the present invention is as follows. (1) Compounds represented by the following formula (I), or salts thereof: (wherein R1 represents a hydrogen atom, C1-6 alkyl, or trifluoromethyl; R2 represents a hydrogen atom, C1-6 alkyl, halogen, -COO(C1-6 alkyl), or -(CH2)1-3COOR (where R represents a hydrogen atom or C1-6 alkyl); R3 represents a hydrogen atom, C1-6 alkyl, amino, trifluoromethyl, or -OR (where R represents a hydrogen atom or C1-6 alkyl); R4 represents a hydroxyl group; R5 represents a hydrogen atom, C1-6 alkyl, hydroxyl group, or halogen; and R6 represents a C1-6 alkyl, trifluoromethyl, halogen, amino, -NRaRb, nitro, or hydroxy C1-6 alkyl R7 represents a hydrogen atom, a C1-6 alkyl group, an OR group (R is a hydrogen atom or a C1-6 alkyl group, Ra and Rb may be the same or different, representing a hydrogen atom, a C1-6 alkyl group, or a C1-6 acyl group), R8 represents a hydrogen atom, a C1-6 alkyl group, an OR group (R is a hydrogen atom or a C1-6 alkyl group), or a halogen group, and R8 represents a hydrogen atom, a C1-6 alkyl group, a hydroxyl group, an amino group, or a nitro group. However, if R1 is a hydrogen atom, R3 is excluded from the hydrogen atom, and compounds where R1 is a tert-butyl group, R3 is an amino group, R4 is a hydroxyl group, and R6 is a methyl group are excluded. (2) The compound or salt thereof described in (1), wherein R1 represents C1-6 alkyl, trifluoromethyl, and R3 represents C1-6 alkyl, trifluoromethyl, -OR (where R represents a hydrogen atom or C1-6 alkyl), (3) The compound or salt thereof described in (1), wherein R1 represents a C1-6 alkyl group and R3 represents a C1-6 alkyl group. (4) R1 represents a C1-4 alkyl group, R2 represents a hydrogen atom, a C1-4 alkyl group, or a halogen, R3 represents a C1-4 alkyl group, R4 represents a hydroxyl group, R5 represents a hydrogen atom, R6 represents a C1-4 alkyl group, trifluoromethyl group, halogen, amino, -NRaRb, nitro, hydroxy C1-4 alkyl group, -CONRaRb, -COO(C1-4 alkyl group), -COOH, -(CH2)1-3COOR, -ORa (where R is a hydrogen atom or a C1-4 alkyl group, and Ra and Rb may be the same or different, representing a hydrogen atom, a C1-4 alkyl group, or a C1-4 acyl group), R7 represents a hydrogen atom, and R8 represents a hydrogen atom, a C1-4 alkyl group, a hydroxyl group, amino, or nitro. The compounds described in (1) or their salts, (5) The compound or salt thereof described in (1), wherein R1 represents methyl, R2 represents a hydrogen atom, methyl, or halogen, R3 represents methyl, R4 represents a hydroxyl group, R5 represents a hydrogen atom, R6 represents a C1-3 alkyl, trifluoromethyl, halogen, amino, -NRaRb, nitro, hydroxy C1-3 alkyl, -CONRaRb, -COO(C1-3 alkyl), -COOH, -(CH2)1-3COOR, -ORa (where R is a hydrogen atom or a C1-3 alkyl, and Ra and Rb may be the same or different, representing a hydrogen atom, a C1-3 alkyl, or a C1-3 acyl), R7 represents a hydrogen atom, and R8 represents a hydrogen atom. Furthermore, (6) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-fluorophenol 2-(5-hydroxy-3-methyl-1H-pyrazole-1-yl)phenol 2-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)phenol 2-(3,5-bistrifluoromethyl)-1H-pyrazole-1-yl)phenol 2-(3-methyl-1H-pyrazole-1-yl)phenol 2-(5-methyl-1H-pyrazole-1-yl)phenol 2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 2-(5-amino-3-tert-butyl-1H-pyrazole-1-yl)phenol 4-chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-chloro-6-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(3,5-diethyl-1H-pyrazole-1-yl)phenol 3-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,2-diol 2-(4-ethyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol 5-fluoro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 4-fluoro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol 1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate ethyl 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propanoate methyl 2-(4-butyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol 5-chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-nitrophenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-nitrophenol 3-(1-(2-hydroqiphenyl)-3,5-Dimethyl-1H-pyrazole-4-yl)propionic acid 5-Chloro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 5-Amino-2-(3,5-Dimethyl-1H-pyrazole-1-yl)phenol 5-Nitro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 4-(3,5-Dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol 5-Amino-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 4-(3,5-Dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylate methyl 3-Amino-2-(3,5-Dimethyl-1H-pyrazole-1-yl)phenol 4-(3,5-Dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylate 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxy-N,N-dimethylbenzamide 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzamide 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzenecarboxylic acid 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzamide 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzamide 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methoxyphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-hydroxymethylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylaminophenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-trifluoromethylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-6-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-ethylphenol, 2-(4-fluoro-3,5-dimethyl-1H-pyrazole-1-yl)phenol, 5-bromo-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol, 5-bromo-2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol, 5-bromo-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol, 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate, 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate, 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenyl acetate, 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methoxy-5-methylphenol, The present invention provides compounds or salts thereof that are 4-chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol, 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4,5-dimethylphenol, or 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-benzene-1,3-diol. In another embodiment, the present invention relates to (7) an anti-dermatophyte agent characterized by containing a compound represented by the following formula (II), or a salt thereof: (wherein R9 represents a hydrogen atom, C1-6 alkyl, or trifluoromethyl; R10 represents a hydrogen atom, C1-6 alkyl, halogen, -COO(C1-6 alkyl), -(CH2)1-3COOR (wherein R represents a hydrogen atom or C1-6 alkyl); R11 represents a hydrogen atom, C1-6 alkyl, amino, trifluoromethyl, -OR (wherein R represents a hydrogen atom or C1-6 alkyl); R12 represents a hydroxyl group; R13 represents a hydrogen atom, C1-6 alkyl, hydroxyl group, or halogen; R14 R15 represents a hydrogen atom, C1-6 alkyl, trifluoromethyl, halogen, amino, -NRaRb, nitro, hydroxy C1-6 alkyl, -CONRaRb, -COO(C1-6 alkyl), -COOH, -(CH2)1-3COOR, -ORa (where R represents a hydrogen atom or C1-6 alkyl, and Ra and Rb may be the same or different, representing a hydrogen atom, C1-6 alkyl, or C1-6 acyl); R15 represents a hydrogen atom, C1-6 alkyl, -OR (where R represents a hydrogen atom or C1-6 alkyl), or halogen; and R16 represents a hydrogen atom, C1-6 alkyl, hydroxyl group, amino, or nitro. (8) An anti-onychomycotic agent characterized by containing the compound or salt thereof described in (1) or (7); (9) The anti-onychomycotic agent described in (7) which is a topical agent; (10) The anti-onychomycotic agent described in (9) which is a topical agent. In this specification, the term "C1-6 alkyl" and the part "C1-6 alkyl" refer to an alkyl group having 1 to 6 carbon atoms. This alkyl group may be linear, branched, or cyclic. Examples include C1-6 alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl, and C3-6 cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In this specification, the term "C1-6 acyl" and the part "C1-6 acyl" refer to an acyl group having 1 to 6 carbon atoms. This acyl group may be linear, branched, or cyclic. Examples include formyl, acetyl, propionyl, butyryl, and isobutyryl. Preferably, examples include formyl, acetyl, propionyl, and butyryl. As used herein, "halogen" refers to fluorine, chlorine, bromine, iodine, and the like. In this specification, the group or part of a group "-OR (where R represents a hydrogen atom or a C1-6 alkyl group)" represents a hydroxyl group or a C1-6 alkyloxy group. "C1-6 alkyl" is synonymous with "C1-6 alkyl" as used herein. In this specification, in the group or part of a group "-ORa", Ra represents a hydrogen atom, C1-6 alkyl, or C1-6 acyl, and "-ORa" represents a hydroxyl group, C1-6 alkyloxy, or C1-6 acyloxy. "C1-6 alkyl" is synonymous with the aforementioned "C1-6 alkyl". In formula (I) above, R1 represents a hydrogen atom, a C1-6 alkyl group, or trifluoromethyl. Preferably, it represents a C1-6 alkyl group or trifluoromethyl, more preferably a C1-6 alkyl group, and even more preferably a C1-3 alkyl group. Specifically, examples include a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, and trifluoromethyl. Even more preferably, examples include a hydrogen atom, methyl, ethyl, butyl, tert-butyl, and trifluoromethyl. Most preferably, methyl is the answer. R2 represents a hydrogen atom, a C1-6 alkyl group, a halogen, -COO(C1-6 alkyl), or -(CH2)1-3COOR (where R represents a hydrogen atom or a C1-6 alkyl group). Preferably, it represents a hydrogen atom, a C1-6 alkyl group, or a halogen, and even more preferably, it represents a hydrogen atom, a C1-3 alkyl group, or a halogen. Specifically, examples include hydrogen atoms, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, chlorine, bromine, fluorine, methyloxycarbonyl, ethyloxycarbonyl, methyloxycarbonylethyl, ethyloxycarbonylethyl, methyloxycarbonylmethyl, ethyloxycarbonylmethyl, hydroxycarbonylmethyl, and hydroxycarbonylethyl. More preferably, examples include hydrogen atoms, methyl, ethyl, butyl, tert-butyl, chlorine, ethyloxycarbonyl, methyloxycarbonylmethyl, and hydroxycarbonylethyl. Most preferably, examples include hydrogen atoms, methyl, and halogens. R3 represents a hydrogen atom, a C1-6 alkyl group, an amino acid, a trifluoromethyl group, or an -OR group (where R represents a hydrogen atom or a C1-6 alkyl group). Preferably, it represents a hydrogen atom, a C1-6 alkyl group, a trifluoromethyl group, or an -OR group (where R represents a hydrogen atom or a C1-6 alkyl group), more preferably a C1-6 alkyl group, and even more preferably a C1-3 alkyl group. Specifically, examples include hydrogen atoms, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, amino, trifluoromethyl, hydroxyl groups, methoxy, and ethoxy. More preferably, examples include hydrogen atoms, methyl, ethyl, amino, trifluoromethyl, and hydroxyl groups. Most preferably, methyl is used. R4 represents a hydroxyl group. R5 represents a hydrogen atom, a C1-6 alkyl group, a hydroxyl group, or a halogen. Preferably, it represents a hydrogen atom or a C1-4 alkyl group. Specifically, examples include hydrogen atoms, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, hydroxyl groups, chlorine atoms, bromine atoms, and fluorine atoms. More preferably, examples include hydrogen atoms, methyl, chlorine atoms, and hydroxyl groups. Even more preferably, examples include hydroxyl groups, chlorine atoms, and methyl, with hydrogen atoms being the most preferred. R6 represents C1-6 alkyl, trifluoromethyl, halogen, amino, -NRaRb, nitro, hydroxy C1-6 alkyl, -CONRaRb, -COO(C1-6 alkyl), -COOH, -(CH2)1-3COOR, -ORa (where R is a hydrogen atom or C1-6 alkyl, and Ra and Rb may be the same or different, representing a hydrogen atom, C1-6 alkyl, or C1-6 acyl). Preferably, examples include C1-4 alkyl, trifluoromethyl, amino, -NRaRb, nitro, hydroxy C1-4 alkyl, -CONRaRb, -COO(C1-4 alkyl), -COOH, -(CH2)1-3COOR, -ORa (where R is a hydrogen atom or C1-4 alkyl, and Ra and Rb may be the same or different, representing a hydrogen atom, C1-4 alkyl, or C1-4 acyl). More preferably, examples include C1-3 alkyl, trifluoromethyl, amino, -NRaRb, nitro, hydroxyC1-3 alkyl, -CONRaRb, -COO(C1-3 alkyl), -COOH, -(CH2)1-3COOR, -ORa (where R is a hydrogen atom or a C1-3 alkyl, and Ra and Rb may be the same or different, representing a hydrogen atom, a C1-3 alkyl, or a C1-3 acyl). Specifically, examples include methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, trifluoromethyl, chlorine atom, bromine atom, fluorine atom, amino, methylamino, ethylamino, dimethylamino, diethylamino, nitro, hydroxymethyl, hydroxyethyl, hydroxypropyl, carbamoyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl, N,N-diethylcarbamoyl, methyloxycarbonyl, ethyloxycarbonyl, -COOH, methyloxycarbonylethyl, ethyloxycarbonylethyl, methyloxycarbonylmethyl, ethyloxycarbonylmethyl, hydroxycarbonylmethyl, hydroxycarbonylethyl, methoxy, ethoxy, acetyloxy, propionyloxy, and hydroxyl groups. More preferably, examples include methyl, ethyl, trifluoromethyl, chlorine atom, fluorine atom, amino, methylamino, nitro, hydroxymethyl, carbamoyl, N,N-dimethylcarbamoyl, methyloxycarbonyl, -COOH, methoxy, acetyloxy, and hydroxyl groups. R7 represents a hydrogen atom, a C1-6 alkyl group, -OR (where R represents a hydrogen atom or a C1-6 alkyl group), or a halogen, preferably a hydrogen atom, a C1-4 alkyl group, or -OR (where R represents a hydrogen atom or a C1-4 alkyl group). Specifically, examples include hydrogen atoms, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propyloxy, hydroxyl groups, chlorine atoms, bromine atoms, and fluorine atoms. Preferably, examples include hydrogen atoms, methyl, methoxy, propyloxy, tert-butyloxy, chlorine atoms, fluorine atoms, and hydroxyl groups. Even more preferably, examples include hydrogen atoms, methyl, methoxy, and chlorine atoms, with hydrogen atoms being the most preferred. R8 represents a hydrogen atom, a C1-6 alkyl group, a hydroxyl group, an amino acid, or a nitro group, preferably a hydrogen atom, a C1-4 alkyl group, a hydroxyl group, an amino acid, or a nitro group, and more preferably a hydrogen atom, a C1-3 alkyl group, a hydroxyl group, an amino acid, or a nitro group. Specifically, examples include hydrogen atoms, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, hydroxyl groups, amino, and nitro. More preferably, examples include hydrogen atoms, methyl, hydroxyl groups, amino, and nitro. Most preferably, examples include hydrogen atoms. However, if R1 is a hydrogen atom, R3 is excluded from the hydrogen atom, and compounds in which R1 is a tert-butyl group, R3 is an amino group, R4 is a hydroxyl group, and R6 is a methyl group are excluded. In formula (II) above, R9 represents a hydrogen atom, a C1-6 alkyl group, or trifluoromethyl. Preferably, examples include a hydrogen atom, a C1-4 alkyl group, or trifluoromethyl. Specifically, examples include a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, or trifluoromethyl. More preferably, examples include a hydrogen atom, methyl, ethyl, butyl, tert-butyl, or trifluoromethyl. R10 represents a hydrogen atom, a C1-6 alkyl group, a halogen, -COO(C1-6 alkyl group), or -(CH2)1-3COOR (where R represents a hydrogen atom or a C1-6 alkyl group). Preferably, examples include a hydrogen atom, a C1-4 alkyl group, a halogen, -COO(C1-4 alkyl group), or -(CH2)1-3COOR (where R represents a hydrogen atom or a C1-4 alkyl group). Specifically, examples include hydrogen atoms, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, chlorine, bromine, fluorine, methyloxycarbonyl, ethyloxycarbonyl, methyloxycarbonylethyl, ethyloxycarbonylethyl, methyloxycarbonylmethyl, ethyloxycarbonylmethyl, hydroxycarbonylmethyl, and hydroxycarbonylethyl. More preferably, examples include hydrogen atoms, methyl, ethyl, butyl, tert-butyl, chlorine, ethyloxycarbonyl, methyloxycarbonylmethyl, and hydroxycarbonylethyl. R11 represents a hydrogen atom, a C1-6 alkyl group, an amino acid, a trifluoromethyl group, or an -OR group (where R represents a hydrogen atom or a C1-6 alkyl group). Preferably, it is a hydrogen atom, a C1-4 alkyl group, an amino acid, a trifluoromethyl group, or an -OR group (where R represents a hydrogen atom or a C1-4 alkyl group). Specifically, it is a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a tert-butyl group, an amino acid, a trifluoromethyl group, a hydroxyl group, or an ethoxy group. More preferably, it is a hydrogen atom, a methyl group, an ethyl group, an amino acid, a trifluoromethyl group, or a hydroxyl group. R12 represents a hydroxyl group. R13 represents a hydrogen atom, a C1-6 alkyl group, a hydroxyl group, or a halogen. Preferably, it represents a hydrogen atom, a C1-4 alkyl group, a hydroxyl group, or a halogen. Specifically, it represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, a hydroxyl group, chlorine, bromine, or fluorine. More preferably, it represents a hydrogen atom, methyl, chlorine, or a hydroxyl group. R14 represents a hydrogen atom, C1-6 alkyl, trifluoromethyl, halogen, amino, -NRaRb, nitro, hydroxy C1-6 alkyl, -CONRaRb, -COO(C1-6 alkyl), -COOH, -(CH2)1-3COOR, -ORa (where R is a hydrogen atom or C1-6 alkyl, and Ra and Rb may be the same or different, representing a hydrogen atom, C1-6 alkyl, or C1-6 acyl). Preferably, examples include hydrogen atoms, C1-4 alkyl groups, trifluoromethyl groups, halogens, amino groups, -NRaRb, nitro groups, hydroxy C1-4 alkyl groups, -CONRaRb, -COO(C1-4 alkyl groups), -COOH groups, -(CH2)1-3COOR groups, -ORa groups (where R represents a hydrogen atom or a C1-4 alkyl group, and Ra and Rb may be the same or different, representing a hydrogen atom, a C1-4 alkyl group, or a C1-4 acyl group). Specifically, examples include hydrogen atoms, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, trifluoromethyl, chlorine, bromine, fluorine, amino, methylamino, ethylamino, dimethylamino, diethylamino, nitro, hydroxymethyl, hydroxyethyl, hydroxypropyl, carbamoyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl, N,N-diethylcarbamoyl, methyloxycarbonyl, ethyloxycarbonyl, -COOH, methyloxycarbonylethyl, ethyloxycarbonylethyl, methyloxycarbonylmethyl, ethyloxycarbonylmethyl, hydroxycarbonylmethyl, hydroxycarbonylethyl, methoxy, ethoxy, acetyloxy, propionyloxy, and hydroxyl groups. More preferably, examples include hydrogen atoms, methyl, ethyl, trifluoromethyl, chlorine, fluorine, amino, methylamino, nitro, hydroxymethyl, carbamoyl, N,N-dimethylcarbamoyl, methyloxycarbonyl, -COOH, methoxy, acetyloxy, and hydroxyl groups. R15 represents a hydrogen atom, a C1-6 alkyl group, an -OR group (where R represents a hydrogen atom or a C1-6 alkyl group), or a halogen. Preferably, examples include a hydrogen atom, a C1-4 alkyl group, an -OR group (where R represents a hydrogen atom or a C1-4 alkyl group), or a halogen. Specifically, examples include a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propyloxy, tert-butyloxy, a hydroxyl group, chlorine, bromine, or fluorine. More preferably, examples include a hydrogen atom, methyl, chlorine, fluorine, or a hydroxyl group. R16 represents a hydrogen atom, a C1-6 alkyl group, a hydroxyl group, an amino acid, or a nitro group. Preferably, it represents a hydrogen atom, a C1-4 alkyl group, a hydroxyl group, an amino acid, or a nitro group. Specifically, it represents a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a tert-butyl group, a hydroxyl group, an amino acid, or a nitro group. More preferably, it represents a hydrogen atom, a methyl group, a hydroxyl group, an amino acid, or a nitro group. The present invention relates to a compound represented by formula (I), or a salt thereof. Another embodiment is an anti-dermatophyte agent characterized by containing a compound represented by formula (II), or a salt thereof. Preferably, an anti-onychomycotic agent is included, and more preferably, a topical anti-dermatophyte agent or a topical anti-onychomycotic agent is included. The present invention relates to a compound represented by formula (I) above, or a salt thereof, where R1 represents a hydrogen atom, C1-6 alkyl, or trifluoromethyl; R2 represents a hydrogen atom, C1-6 alkyl, halogen, -COO(C1-6 alkyl), or -(CH2)1-3COOR (where R represents a hydrogen atom or C1-6 alkyl); R3 represents a hydrogen atom, C1-6 alkyl, amino, trifluoromethyl, or -OR (where R represents a hydrogen atom or C1-6 alkyl); R4 represents a hydroxyl group; R5 represents a hydrogen atom, C1-6 alkyl, hydroxyl group, or halogen; and R6 represents a C1-6 alkyl, trifluoromethyl, halogen, amino, -NRaRb, nitro, or hydroxyC1- R7 represents a hydrogen atom, a C1-6 alkyl group, a C1-6 alkyl group, a COOH group, a CH2 1-3 COOR group, or a C1-6 acyl group (where R is a hydrogen atom or a C1-6 alkyl group, and Ra and Rb may be the same or different, representing a hydrogen atom, a C1-6 alkyl group, or a C1-6 acyl group); R7 represents a hydrogen atom, a C1-6 alkyl group, a OR group (where R is a hydrogen atom or a C1-6 alkyl group), or a halogen; and R8 represents a hydrogen atom, a C1-6 alkyl group, a hydroxyl group, an amino acid, or a nitro group. However, if R1 is a hydrogen atom, R3 is excluded from the hydrogen atom, and compounds in which R1 is a tert-butyl group, R3 is an amino group, R4 is a hydroxyl group, and R6 is a methyl group are excluded. Preferably, in formula (I), R1 represents a hydrogen atom, a C1-4 alkyl group, or a trifluoromethyl group; R2 represents a hydrogen atom, a C1-4 alkyl group, a halogen, -COO(C1-4 alkyl), or -(CH2)1-3COOR (where R represents a hydrogen atom or a C1-4 alkyl group); R3 represents a hydrogen atom, a C1-4 alkyl group, an amino acid, a trifluoromethyl group, or -OR (where R represents a hydrogen atom or a C1-4 alkyl group); R4 represents a hydroxyl group; R5 represents a hydrogen atom, a C1-4 alkyl group, a hydroxyl group, or a halogen; and R6 represents a C1-4 alkyl group, a trifluoromethyl group, a halogen, an amino acid, -NRaRb, a nitro acid, a hydroxyC1-4 alkyl group, or -CON RaRb represents -COO(C1-4 alkyl), -COOH, -(CH2)1-3COOR, -ORa (where R is a hydrogen atom or a C1-4 alkyl group, and Ra and Rb may be the same or different, representing a hydrogen atom, a C1-4 alkyl group, or a C1-4 acyl group); R7 represents a hydrogen atom, a C1-4 alkyl group, -OR (where R is a hydrogen atom or a C1-4 alkyl group), or a halogen; and R8 represents a hydrogen atom, a C1-4 alkyl group, a hydroxyl group, an amino acid, or a nitro group (however, if R1 is a hydrogen atom, R3 is excluded from the hydrogen atom, and compounds where R1 is a tert-butyl group, R3 is an amino group, R4 is a hydroxyl group, and R6 is a methyl group are excluded). Specific examples of preferred substituents in formula (I) are, wherein the formula, R1 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, or trifluoromethyl, and R2 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, chlorine atom, bromine atom, fluorine atom, methyloxycarbonyl, ethyloxycarbonylethyl, ethyloxycarbonylethyl, methyloxycarbonylmethyl, ethyloxycarbonylmethyl, hydroxycarbonylmethyl, or hydroxycarbonylethyl R3 represents hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, amino, trifluoromethyl, hydroxyl group, methoxy, ethoxy; R4 represents hydroxyl group; R5 represents hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, hydroxyl group, chlorine atom, bromine atom, fluorine atom; R6 represents methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, trifluoromethyl, chlorine atom, bromine atom, fluorine atom, amino, methylamino, ethylamino, dimethylamino, di Ethylamino, nitro, hydroxymethyl, hydroxyethyl, hydroxypropyl, carbamoyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl, N,N-diethylcarbamoyl, methyloxycarbonyl, ethyloxycarbonyl, -COOH, methyloxycarbonylethyl, ethyloxycarbonylethyl, methyloxycarbonylmethyl, ethyloxycarbonylmethyl, hydroxycarbonylmethyl, hydroxycarbonylethyl, methoxy, ethoxy, acetyloxy, propionyloxy R7 represents a hydroxyl group, and R7 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propyloxy, tert-butyloxy, hydroxyl group, chlorine atom, bromine atom, or fluorine atom. R8 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, hydroxyl group, amino, or nitro (however, if R1 is a hydrogen atom, R3 is excluded from the hydrogen atom, and compounds in which R1 is a tert-butyl group, R3 is an amino group, R4 is a hydroxyl group, and R6 is a methyl group are excluded). More preferably, R1 represents methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, or trifluoromethyl, and R2 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, chlorine atom, bromine atom, fluorine atom, methyloxycarbonyl, ethyloxycarbonylethyl, ethyloxycarbonylethyl, methyloxycarbonylmethyl, ethyloxycarbonylmethyl, hydroxycarbonylmethyl, or hydroxycarbonylethyl. R3 represents methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, trifluoromethyl, hydroxyl group, methoxy, ethoxy; R4 represents hydroxyl group; R5 represents hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, hydroxyl group, chlorine atom, bromine atom, fluorine atom; R6 represents methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, trifluoromethyl, chlorine atom, bromine atom, fluorine atom, amino, methylamino, ethylamino, dimethylamino, die Tylamino, Nitro, Hydroxymethyl, Hydroxyethyl, Hydroxypropyl, Carbamoyl, N-Methylcarbamoyl, N,N-Dimethylcarbamoyl, N-Ethylcarbamoyl, N,N-Diethylcarbamoyl, Methyloxycarbonyl, Ethyloxycarbonyl, -COOH, Methyloxycarbonylethyl, Ethyloxycarbonylethyl, Methyloxycarbonylmethyl, Ethyloxycarbonylmethyl, Hydroxycarbonylmethyl, Hydroxycarbonylethyl, Methoxy, Ethoxy, Acetyl R7 represents a hydroxyl group, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propyloxy, tert-butyloxy, hydroxyl group, chlorine atom, bromine atom, or fluorine atom, while R8 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, hydroxyl group, amino, or nitro (excluding compounds where R1 is a tert-butyl group, R3 is an amino group, R4 is a hydroxyl group, and R6 is a methyl group). More preferably, R1 represents methyl, ethyl, propyl, isopropyl, butyl, and tert-butyl; R2 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, a chlorine atom, a bromine atom, a fluorine atom, methyloxycarbonyl, ethyloxycarbonyl, methyloxycarbonylethyl, ethyloxycarbonylethyl, methyloxycarbonylmethyl, ethyloxycarbonylmethyl, hydroxycarbonylmethyl, and hydroxycarbonylethyl; R3 represents methyl, ethyl, propyl, isopropyl, butyl, and tert-butyl; R4 represents a hydroxyl group; R5 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, a hydroxyl group, a chlorine atom, a bromine atom, and a fluorine atom; and R6 represents methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, trifluoromethyl, a chlorine atom, a bromine atom, a fluorine atom, amino, methylamino, and ethylamino. R7 represents a hydroxyl group, methyl, ethyl, diethylamino, nitro, hydroxymethyl, hydroxyethyl, hydroxypropyl, carbamoyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl, N,N-diethylcarbamoyl, methyloxycarbonyl, ethyloxycarbonyl, -COOH, methyloxycarbonylethyl, ethyloxycarbonylethyl, methyloxycarbonylmethyl, ethyloxycarbonylmethyl, hydroxycarbonylmethyl, hydroxycarbonylethyl, methoxy, ethoxy, acetyloxy, propionyloxy. R7 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propyloxy, tert-butyloxy, hydroxyl group, chlorine atom, bromine atom, fluorine atom, and R8 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, hydroxyl group, amino, and nitro. A more preferred formula (I) is one in which R1 represents methyl, ethyl, propyl, isopropyl, butyl, or tert-butyl; R2 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, chlorine atom, bromine atom, or fluorine atom; R3 represents methyl, ethyl, propyl, isopropyl, butyl, or tert-butyl; R4 represents a hydroxyl group; R5 represents a hydrogen atom; and R6 represents methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, trifluoromethyl, chlorine atom, bromine atom, fluorine atom, amino, methylamino, ethylamino, dimethylamino, diethylamino, nitro, hydroxymethyl, or hydroxyethyl R7 represents a hydrogen atom, and R8 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, hydroxyl group, amino, and nitro. Most preferably, R1 represents methyl, R2 represents a hydrogen atom, methyl, or chlorine atom, R3 represents methyl, R4 represents a hydroxyl group, R5 represents a hydrogen atom, and R6 represents methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, trifluoromethyl, chlorine atom, bromine atom, fluorine atom, amino, methylamino, ethylamino, dimethylamino, diethylamino, nitro, hydroxymethyl, hydroxyethyl, hydroxypropyl, carbamoyl, or N-methylcarbamoyl. R7 represents a hydrogen atom, and R8 represents a hydrogen atom. The present invention is an anti-dermatophyte agent characterized by containing a compound represented by formula (II) or a salt thereof (wherein R9 represents a hydrogen atom, C1-6 alkyl, or trifluoromethyl; R10 represents a hydrogen atom, C1-6 alkyl, halogen, -COO(C1-6 alkyl), -(CH2)1-3COOR (wherein R represents a hydrogen atom or C1-6 alkyl); R11 represents a hydrogen atom, C1-6 alkyl, amino, trifluoromethyl, or -OR (wherein R represents a hydrogen atom or C1-6 alkyl); R12 represents a hydroxyl group; R13 represents a hydrogen atom, C1-6 alkyl, hydroxyl group, or halogen; R1 R15 represents a hydrogen atom, C1-6 alkyl, trifluoromethyl, halogen, amino, -NRaRb, nitro, hydroxy C1-6 alkyl, -CONRaRb, -COO(C1-6 alkyl), -COOH, -(CH2)1-3COOR, -ORa (where R is a hydrogen atom or C1-6 alkyl, and Ra and Rb may be the same or different, representing a hydrogen atom, C1-6 alkyl, or C1-6 acyl); R15 represents a hydrogen atom, C1-6 alkyl, -OR (where R is a hydrogen atom or C1-6 alkyl), or halogen; and R16 represents a hydrogen atom, C1-4 alkyl, hydroxyl group, amino, or nitro). Preferably, R9 represents a hydrogen atom, C1-4 alkyl, or trifluoromethyl; R10 represents a hydrogen atom, C1-4 alkyl, halogen, -COO(C1-4 alkyl), or -(CH2)1-3COOR (where R represents a hydrogen atom or C1-4 alkyl); R11 represents a hydrogen atom, C1-4 alkyl, amino, trifluoromethyl, or -OR (where R represents a hydrogen atom or C1-4 alkyl); R12 represents a hydroxyl group; R13 represents a hydrogen atom, C1-4 alkyl, hydroxyl group, or halogen; and R14 represents a hydrogen atom, C1-4 alkyl, or trifluoromethyl R15 represents a hydrogen atom, a halogen, an amino acid, -NRaRb, a nitro acid, a hydroxy C1-4 alkyl group, -CONRaRb, -COO (C1-4 alkyl group), -COOH, -(CH2)1-3COOR, -ORa (where R is a hydrogen atom or a C1-4 alkyl group, and Ra and Rb may be the same or different, representing a hydrogen atom, a C1-4 alkyl group, or a C1-4 acyl group). R15 represents a hydrogen atom, a C1-4 alkyl group, -OR (where R is a hydrogen atom or a C1-4 alkyl group), or a halogen group. R16 represents a hydrogen atom, a C1-4 alkyl group, a hydroxyl group, an amino acid, or a nitro acid group. A more preferred formula (II) is in which R9 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, or trifluoromethyl, and R10 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, chlorine atom, bromine atom, fluorine atom, methyloxycarbonyl, ethyloxycarbonyl, methyloxycarbonylethyl, ethyloxycarbonylethyl, methyloxycarbonylmethyl, ethyloxycarbonylmethyl, or hydroxycarbonylmethyl R11 represents hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, amino, trifluoromethyl, hydroxyl group, methoxy, ethoxy; R12 represents hydroxyl group; R13 represents hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, hydroxyl group, chlorine atom, bromine atom, fluorine atom; R14 represents hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, trifluoromethyl, salt Elementary atom, bromine atom, fluorine atom, amino, methylamino, ethylamino, dimethylamino, diethylamino, nitro, hydroxymethyl, hydroxyethyl, hydroxypropyl, carbamoyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl, N,N-diethylcarbamoyl, methyloxycarbonyl, ethyloxycarbonyl, -COOH, methyloxycarbonylethyl, ethyloxycarbonylethyl, methyloxycarbonylmethyl, ethyloxycarbonyl R15 represents a hydroxyl group, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, acetyloxy, proopionyloxy, and hydroxyl group. R16 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propyloxy, tert-butyloxy, hydroxyl group, chlorine atom, bromine atom, and fluorine atom. R16 represents a hydrogen atom, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, hydroxyl group, amino, and nitro. More preferably, R9 represents a hydrogen atom, methyl, ethyl, butyl, tert-butyl, or trifluoromethyl; R10 represents a hydrogen atom, methyl, ethyl, butyl, tert-butyl, fluorine atom, chlorine atom, ethyloxycarbonyl, methyloxycarbonylmethyl, or hydroxycarbonylethyl; R11 represents a hydrogen atom, methyl, ethyl, amino, trifluoromethyl, or a hydroxyl group; R12 represents a hydroxyl group; R13 represents a hydrogen atom, methyl, chlorine atom, or a hydroxyl group; R14 represents a hydrogen atom, methyl, ethyl, trifluoromethyl, chlorine atom, fluorine atom, amino, methylamino, nitro, hydroxymethyl, carbamoyl, N,N-dimethylcarbamoyl, methyloxycarbonyl, -COOH, methoxy, acetyloxy, or a hydroxyl group; R15 represents a hydrogen atom, methyl, methoxy, chlorine atom, fluorine atom, or a hydroxyl group; and R16 represents a hydrogen atom, methyl, hydroxyl group, amino, or nitro. The specific compounds of formula (I) or (II) are: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-fluorophenol 2-(5-hydroxy-3-methyl-1H-pyrazole-1-yl)phenol 2-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)phenol 2-(3,5-bistrifluoromethyl)-1H-pyrazole-1-yl)phenol 2-(3-methyl-1H-pyrazole-1-yl)phenol 2-(5-methyl-1H-pyrazole-1-yl)phenol 2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 2-(5-amino-3-tert-butyl-1H-pyrazole-1-yl)phenol 4-chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-Chloro-6-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(3,5-diethyl-1H-pyrazole-1-yl)phenol 3-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,2-diol 2-(4-ethyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol 5-Fluoro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 4-Fluoro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol 1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate ethyl 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propanoate methyl 2-(4-butyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol 5-chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-nitrophenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-nitrophenol 3-(1-(2-hydroxyphenyl)-3,5-Dimethyl-1H-pyrazole-4-yl)propionic acid 5-Chloro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 5-Amino-2-(3,5-Dimethyl-1H-pyrazole-1-yl)phenol 5-Nitro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 4-(3,5-Dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol 5-Amino-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 4-(3,5-Dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylate methyl 3-Amino-2-(3,5-Dimethyl-1H-pyrazole-1-yl)phenol 4-(3,5-Dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylate 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxy-N,N-dimethylbenzamide 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzamide 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzenecarboxylic acid 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzamide 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzamide 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methoxyphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-hydroxymethylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylaminophenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-trifluoromethylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-6-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-ethylphenol, 2-(4-fluoro-3,5-dimethyl-1H-pyrazole-1-yl)phenol, 5-bromo-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol, 5-bromo-2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol, 5-bromo-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol, 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate, 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate, 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenyl acetate, 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methoxy-5-methylphenol, It is a compound or salt of 4-chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol, 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4,5-dimethylphenol, or 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-benzene-1,3-diol. Furthermore, specific compounds in formula (II) where R14 is a hydrogen atom are: 2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-fluorophenol 2-(1H-pyrazole-1-yl)phenol 2-(5-hydroxy-3-methyl-1H-pyrazole-1-yl)phenol 2-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)phenol 2-(3,5-bistrifluoromethyl)-1H-pyrazole-1-yl)phenol 2-(3-methyl-1H-pyrazole-1-yl)phenol 2-(5-methyl-1H-pyrazole-1-yl)phenol 2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 2-(5-amino-3-tert-butyl-1H-pyrazole-1-yl)phenol 4-Chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-Chloro-6-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(3,5-diethyl-1H-pyrazole-1-yl)phenol 3-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,2-diol 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,4-diol 2-(4-ethyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,4-diol 4-Fluoro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate ethyl 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propanoate methyl 2-(4-butyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-nitrophenol 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propionic acid 3-amino-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol, 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methylphenol, 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methylphenol, 2-(3,5-dimethyl-1H-pyrazole-1-yl)-6-methylphenol, 2-(4-fluoro-3,5-dimethyl-1H-pyrazole-1-yl)phenol, or a salt thereof. Furthermore, in yet another embodiment, the anti-dermatophyte agent is characterized by containing a compound or a salt thereof described in any one of (1) to (6) above. More preferably, the anti-onychomycosis agent is characterized by containing a compound or a salt thereof described in any one of (1) to (6) above. The compounds of the present invention can take the form of salts. Specifically, they can be used in the form of pharmaceutically acceptable salts derived from inorganic acids, organic acids, or bases. "Pharmaceutically acceptable salts" are well known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in the Journal of Pharmaceutical Sciences, 66, pp. 1 onwards (1977). Typical acid addition salts include, but are not limited to, inorganic acid salts such as hydrochloride, sulfate, nitrate, hydrobromide, hydroiodide, and phosphate; organic carboxylate salts such as acetate, trifluoroacetate, lactate, citrate, oxalate, succinate, glutarate, malate, tartrate, fumarate, mandelate, maleate, benzoate, nicotinate, and phthalate; organic sulfonates such as methanesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, benzenesulfonate, p-toluenesulfonate, 2-naphthalenesulfonate, and camphorsulfonate; and acidic amino acid salts such as aspartate and glutamate. Preferred acid addition salts include, but are not limited to, salts with inorganic acids such as hydrochloric acid, hydrobromide, sulfuric acid, and phosphoric acid, and organic acids such as oxalic acid, maleic acid, methanesulfonic acid, p-toluenesulfonic acid, and citric acid. More preferably, the salt is with hydrochloric acid, hydrobromic acid, sulfuric acid, or methanesulfonic acid. Base addition salts can be produced in situ by reacting a carboxylic acid or phenolic hydroxyl group-containing portion with a suitable base during the final isolation and purification process of the compound of the present invention. Pharmaceutically acceptable salts include, but are not limited to, alkali metal salts such as lithium salts, sodium salts, and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; aluminum salts; ammonium salts; and organic base salts such as methylamine salt, dimethylamine salt, ethylamine salt, diethylamine salt, trimethylamine salt, triethylamine salt, tetramethylammonium salt, tetraethylammonium salt, pyridine salt, picoline salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, trishydroxymethylaminomethane salt, piperidine salt, piperazine salt, dicyclohexylamine salt, and N,N-dibenzylethylenediamine salt; and basic amino acid salts such as arginine salt, lysine salt, and ornithine salt. Preferred base addition salts include addition salts with sodium, potassium, calcium, ethanolamine, and trishydroxymethylaminomethane. More preferably, it is an addition salt with sodium, potassium, and trishydroxymethylaminomethane. Furthermore, the compounds of the present invention may also be used in the form of solvates. As used herein, the term "solvate" means a complex of various stoichiometric values formed by a solute (a compound of formula (I) or formula (II) or a salt thereof in the present invention) and a solvent. Such solvents for the purposes of the present invention are preferably pharmaceutically acceptable solvents that do not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, methanol, ethanol, ethylene glycol, propylene glycol, ethyl acetate, and butyl acetate. Preferably, solvents for solvates include water, ethanol, and ethyl acetate. Compound (I) or (II) of the present invention can be safely administered orally or parenterally in pharmaceutical compositions mixed with a pharmaceutically acceptable carrier according to known methods, such as tablets (including sugar-coated tablets and film-coated tablets), powders, granules, capsules (including soft capsules), liquids, injections, suppositories, sustained-release preparations, lotions, liniments, poultices, ointments, patches, alcoholic preparations, suspensions, emulsions, transdermal formulations, liquids, creams, aerosols, nail lacquers, etc. Pharmacologically acceptable carriers that may be used in the manufacture of the formulations of the present invention include various organic or inorganic carrier substances commonly used as formulation materials, such as excipients, lubricants, binders, and disintegrants in solid formulations; and solvents, solubilizers, suspending agents, isotonic agents, buffers, and analgesics in liquid formulations. In addition, conventional additives such as preservatives, antioxidants, colorants, sweeteners, adsorbents, and wetting agents may be used as needed. Examples of excipients include lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, and light anhydrous silicic acid. Examples of lubricants include magnesium stearate, calcium stearate, talc, and colloidal silica. Examples of binders include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, sucrose, gelatin, methylcellulose, and sodium carboxymethylcellulose. Examples of disintegrants include starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, carboxymethyl starch sodium, and L-hydroxypropylcellulose. Examples of solvents include sterile water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, and olive oil. Examples of solubilizers include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, and sodium citrate. Examples of suspending agents include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate; and hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose. Examples of isotonic agents include glucose, D-sorbitol, sodium chloride, glycerin, and D-mannitol. Examples of buffering agents include buffer solutions such as phosphates, acetates, carbonates, and citrates. Examples of pain-relieving agents include benzyl alcohol. Examples of preservatives include para-hydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, and sorbic acid. Examples of antioxidants include sulfites, ascorbic acid, and α-tocopherol. The present invention is preferably a topical preparation and can be applied without particular limitations as long as it is a dosage form used in topical pharmaceutical compositions. Suitable examples include lotions, liniments, poultices, ointments, patches, alcoholic preparations, suspensions, emulsions, transdermal formulations, liquids, creams, aerosols, and nail lacquers. Particularly preferred are nail lacquers, lotions, liquids, creams, and patches. The external anti-dermatophyte agent of the present invention can contain any component usually used in pharmaceutical compositions within a range that does not impair the effects of the present invention. Such components include, for example, hydrocarbons such as petrolatum and microcrystalline wax, esters such as jojoba oil, whale oil, triacetin, triethyl citrate, and butyl acetate, triglycerides such as beef tallow and olive oil, higher alcohols such as cetanol and oleyl alcohol, fatty acids such as stearic acid and oleic acid, alcohols such as ethanol and isopropanol, polyhydric alcohols such as glycerin and 1,3-butanediol, water, nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, thickeners such as polyvinylpyrrolidone and carbopol, preservatives, ultraviolet absorbers, antioxidants, pigments, powders, and the like. By treating these optional components and the formula (I) or (II) according to a conventional method, the external pharmaceutical composition of the present invention can be produced. The content of the compound (I) or (II) in the preparation of the present invention is about 0.01 to 100% by weight of the whole preparation. Although the dosage varies depending on the administration subject, administration route, disease, etc., for example, as an anti-dermatophyte agent, when administered externally to adults, as the active ingredient compound (I) or (II), it can be administered at 0.5 - 15% in divided doses of once to several times a day. It can also be administered once every 2 to 7 days. Administration is preferably carried out daily. In particular, for onychomycosis, since the present invention has high permeability, it is possible to significantly transfer the active ingredient into the nail compared to conventional external agents. As a result, it is possible to treat onychomycosis only by external application without taking an antifungal agent orally for a long time. Also, recurrence and reinfection are major problems in onychomycosis, but by administering the external anti-dermatophyte agent of the present invention for 1 to 2 weeks after symptom relief, such recurrence and reinfection can be prevented. In this form, the external anti-dermatophyte agent of the present invention exhibits a preventive effect. An antifungal agent having strong antifungal activity against Trichophyton rubrum has been provided. Further, since the compound of the present invention has a remarkable effect on nail permeability, it has been possible to provide a topical antifungal agent for onychomycosis, which has been difficult to treat conventionally. As a result, it is possible to avoid drug interactions, liver damage, and side effects due to long-term administration, which have been problems with conventional oral antifungal agents, and it has become possible to treat onychomycosis in elderly people and diabetic patients who may be taking multiple drugs. The compound of formula (I) and formula (II) of the present invention or a salt thereof can be obtained by, for example, a method represented by the following reaction formula or a method analogous thereto. The production method is shown in the following figure, and each symbol of the compounds in the figure has the same meaning as described above. Further, formula (II) is synonymous except for the definition of some substituents, and since formula (II) can be produced in the same manner as formula (I), it will be described by formula (I) in this section. The 2-(1H-pyrazol-1-yl)phenol derivative represented by the general formula (I) can be synthesized by the method shown in Scheme 1. In Scheme 1, P and P' represent hydrogen or a suitable protecting group, X represents a halogen or a suitable boronic acid group, and Y represents the dissociation ion of the acid used in the reaction. In the present specification, "suitable boronic acid" represents boronic acid or boronic acid ester. The method of obtaining the hydrazine derivative (V) or a salt thereof via the diazonium compound (IVa) from the 2-hydroxyaniline derivative (IIIa) or a salt thereof can be carried out according to the methods described in Organic Synthesis Collective Volume 1, p. 442-445, J.Org.Chem., Vol. 21, p. 394-399, 1956, WO2007 / 083320, and US6852890. The diazotization reaction can be carried out using nitrites such as potassium nitrite, calcium nitrite, silver nitrite, sodium nitrite, and barium nitrite, or nitrite esters such as nitrosyl sulfate, ethyl nitrite, isoamyl nitrite, isobutyl nitrite, isopropyl nitrite, tert-butyl nitrite, n-butyl nitrite, and n-propyl nitrite. Preferably, sodium nitrite or nitrite esters such as isoamyl nitrite and tert-butyl nitrite are used. When using protecting groups, any group that is inert in steps other than deprotection may be used. Examples of P and P' include alkyl groups such as methyl, isopropyl, allyl, tert-butyl, methoxymethyl, methylthiomethyl, benzyl, and 9-anthrylmethyl groups, or acyl groups such as pivaloyl and benzoyl groups, or sulfonyl groups such as p-toluenesulfonyl and methanesulfonyl groups, but are not limited to these. Preferred protecting groups include methyl, p-toluenesulfonyl, and methanesulfonyl groups. The amount of reagent used in the diazotization reaction is preferably 1 to 10 equivalents, and more preferably 1 to 3 equivalents, relative to the 2-hydroxyaniline derivative (IIIa). When using nitrites in the above diazotization reaction, water, or organic solvents mixed with water in any proportion, such as methanol, ethanol, 2-propanol, acetic acid, trifluoroacetic acid, tetrahydrofuran, 1,4-dioxane, dimethylformamide, and dimethyl sulfoxide, can be used. Furthermore, a mixture of multiple of these solvents can also be used. Preferably, water, a water-methanol mixture, or a water-methanol-acetic acid mixture are used. In addition, to ensure the solubility of the aniline derivative substrate and to generate nitrite in the reaction system, the diazotization reaction is carried out under acidic conditions. Examples of acids that can be used include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, acetic acid, trifluoroacetic acid, and phosphoric acid. Preferably, hydrochloric acid, acetic acid, and trifluoroacetic acid are used. Furthermore, these acids can also be used as solvents. In the diazotization reaction described above, when using nitrite esters, alcohols such as methanol, ethanol, methoxyethanol, ethoxyethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, and 2-methyl-2-propanol, ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methyl-tert-butyl ether, diphenyl ether, and 1,4-dioxane, acetate esters such as methyl acetate, ethyl acetate, propyl acetate, and butyl acetate, aprotic solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, and dimethyl sulfoxide, and halogen solvents such as dichloromethane, chloroform, and 1,2-dichloroethane can be used. Furthermore, a mixture of several of these solvents can also be used. Preferably, a mixture of methanol, ethanol, and ethanol-diethyl ether is used. The temperature for the above diazotization reaction is preferably -50°C to 50°C, and more preferably between -30°C and 10°C, regardless of whether a nitrite or nitrite ester is used. Even more preferably, it is between -10°C and 5°C. The above diazotization reaction, depending on the substrate and reaction conditions, takes between 5 minutes and 12 hours, but is usually completed within 3 hours. The concentration of the substrate in the above diazotization reaction solution is not particularly limited, but can be in the range of 0.1 mM to 10 M. Preferably, it is in the range of 1 mM to 1 M. For the reduction of diazonium compounds (IVa) to hydrazine derivatives (V), stannous chloride or its hydrate, sulfite, bisulfite, dithionite, or triphenylphosphine can be used (Organic Synthesis Collective Volume 1, pp. 442-445, J.Org.Chem., Vol. 21, pp. 394-399, 1956, WO2007 / 083320, US6852890, US2007 / 0105866, J.Am.Chem.Soc., Vol. 92, pp. 853-859, 1970). Preferably, the method uses stannous chloride, dithionite, or sulfite. The above reduction reaction can be carried out following the diazotization reaction. That is, without isolating the generally unstable diazonium compound, it is possible to synthesize the hydrazine derivative (V) or its salt by adding the reducing reagent to the reaction mixture, or by adding the diazotization reaction solution to a solution of the reducing reagent. The amount of the reducing agent is preferably 1 to 30 equivalents, and more preferably 1 to 10 equivalents, relative to the corresponding diazonium compound. The solvent used in the reduction reaction described above may be the same as the solvent used in the diazotization reaction, or additional solvents may be added as appropriate, but it is preferable to use the same solvent as in the diazotization reaction. The temperature of the above reduction reaction varies depending on the type of reducing agent, but is preferably between -50°C and 120°C, and more preferably between -10°C and 70°C. Even more preferably between -10°C and 30°C. Hydrazine derivative (V) or its salts can also be synthesized from compound (IIIb) without going through the diazonium compound (IVa). That is, hydrazine derivative (V) or its salts can also be obtained by reacting compound (IIIb) with hydrazine or P'-protected hydrazine, either in the presence or absence of a suitable catalyst. Phenylpyrazole derivatives (VI) can also be synthesized by reacting compound (IIIb) with a suitable pyrazole, either in the presence or absence of a suitable catalyst. When using hydrazine bonded with a protecting group P', any inert group other than deprotection may be used. Examples of P' include alkyloxycarbonyl groups such as methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, and benzyloxycarbonyl groups, or acyl groups such as pivaloyl and benzoyl groups, or sulfonyl groups such as p-toluenesulfonyl and methanesulfonyl groups, but are not limited to these. A preferred protecting group is the t-butoxycarbonyl group. If X in compound (IIIb) is a halogen, the procedure can be carried out according to the method described in Organic Letters Vol.3, pp.3803-3805, 2001; J.Org.Chem., Vol.72, pp.6190-6199, 2007; and J.Org.Chem., Vol.70, pp.5164-5173, 2005. If X in compound (IIIb) is a boronic acid, the procedure can be carried out according to the method described in Bioorg. Med. Chem. Lett., Vol.18, pp.4438-4441, 2008. The amount of hydrazine, P'-protected hydrazine, or pyrazole used in the above reaction is preferably 1 to 30 equivalents, and more preferably 1 to 5 equivalents, relative to compound (IIIb). Suitable solvents for the above reaction vary depending on the substrate and reaction conditions, but include, but are not limited to, aprotic solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, sulfolane, acetonitrile, and propionitrile; ether solvents such as 1,4-dioxane, 1,2-dimethoxyethane, and 1,2-diethoxyethane; and halogenated solvents such as chloroform, 1,2-dichloroethane, 1,1,2,2-tetrachloroethane, and 1,1,1-trichloroethane. Furthermore, multiple solvents can be mixed and used. If the substrate is a liquid, the reaction can be carried out without a solvent. Preferably, N,N-dimethylformamide, N-methylpyrrolidone, propionitrile, or dimethyl sulfoxide is used, or the reaction is carried out without a solvent. In the above reaction, in addition to salts of copper or palladium, copper or palladium coordinated with a suitable ligand can be used in catalytic or stoichiometric amounts. In this case, it is preferable to use organic bases such as 1,4-diazabicyclo[2,2,2]octane, 1,8-diazabicyclo[5,4,0]undecene, pyridine, N,N-dimethylaminopyridine, tert-butoxypotassium, tert-butoxysodium, or inorganic bases such as potassium carbonate, cesium carbonate, or potassium phosphate. More preferably, pyridine, potassium carbonate, cesium carbonate, or potassium phosphate are used. Suitable ligands include, but are not limited to, tributylphosphine, triphenylphosphine, N-methylglycine, N,N-dimethylglycine, 1,2-diaminocyclohexane, 1,10-phenantholine derivatives, 8-hydroxyquinoline, picolinic acid, and 2,2'-bipyridine. Preferably, N,N-dimethylglycine, 1,2-diaminocyclohexane, and 8-hydroxyquinoline are used. Adding small amounts of water, polyethylene glycol, etc., can sometimes improve the results of the above reaction. When X in compound (IIIb) is a boronic acid, favorable results can sometimes be obtained by appropriately blowing air or oxygen into the reaction system. The reaction temperature described above varies depending on the type of substrate and the presence and type of catalyst, but is preferably between 10°C and 200°C, and more preferably between 20°C and 150°C. Irradiation with microwaves may accelerate the reaction. The above reactions vary depending on the type of substrate and the presence and type of catalyst, but they usually complete within 15 minutes to 96 hours, and are typically completed within 48 hours. The substrate concentration in the above reaction is not particularly limited, but is usually 1 mM to neat (solvent-free). Preferably it is 10 mM to 10 M. The deprotection reaction from compound (IVb) to (V) or its salt can be carried out using an appropriate method depending on the P' used, as described in Green, Protective Groups in Organic Synthesis (5th), 1999, John Wieley & Sons. Specifically, when P' is a tert-butoxycarbonyl group, it is preferable to use an acid such as hydrochloric acid or trifluoroacetic acid. In this case, the presence of anisole or thioanisole may yield favorable results. The obtained hydrazine derivative (V) or its salt can be reacted with a 1,3-diketone or its chemical equivalent to synthesize a phenylpyrazole derivative (VI) that forms a pyrazole ring. Here, a chemical equivalent refers to a compound in which the carbonyl group is protected with an acetal group, and which can be easily converted to a ketone group by an acid present in the system during the pyrazole ring formation reaction. The amount of 1,3-diketone or its chemical equivalent used in the above reaction is preferably 1 to 20 equivalents, and more preferably 1 to 5 equivalents, relative to compound (V). Suitable solvents for the above reaction vary depending on the substrate and reaction conditions, but include alcohols such as methanol, ethanol, methoxyethanol, ethoxyethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-2-propanol, glycerol, and 1,3-propanediol, as well as diethyl ether, diisopropyl ether, tetrahydrofuran, methyl-tert-butyl ether, diphenyl ether, 1,4-dioxane, diethylene glycol dimethyl ether, and 1,2-dimethoxyethanol. Examples of solvents include, but are not limited to, ether-based solvents such as tan and 1,2-diethoxyethane; acetic acid esters such as methyl acetate, ethyl acetate, propyl acetate and butyl acetate; aprotic solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, acetonitrile and propionitrile; and halogen-based solvents such as dichloromethane, chloroform, 1,2-dichloroethane, 1,1,2,2-tetrachloroethane and 1,1,1-trichloroethane. Furthermore, multiple solvents can be mixed and used. Methanol, ethanol, 2-propanol, 1,2-dimethoxyethane and N,N-dimethylformamide are preferred. When using the hydrazine derivative (V) as a free form in the above reaction, a suitable acid can be added in a catalytic amount or 1 equivalent or more. Suitable acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, acetic acid, trifluoroacetic acid, and phosphoric acid. Hydrochloric acid and trifluoroacetic acid are preferred. The reaction temperature described above varies depending on the type of substrate, but is preferably between 10°C and 200°C, and more preferably between 40°C and 120°C. The above reaction, although varying depending on the type of substrate, usually takes 15 minutes to 24 hours, and is often completed within 12 hours. The substrate concentration in the above reaction is not particularly limited, but is usually 0.1 mM to 1 M. Preferably, it is 10 mM to 1 M. The obtained phenylpyrazole derivative (VI) can be converted to compound (I) of the present invention by deprotection of the protecting group if necessary. The deprotection reaction can be carried out using an appropriate method depending on the P used, as described in Green, Protective Groups in Organic Synthesis (5th), 1999, John Wieley & Sons. When P is a methyl group, boron tribromide or aluminum chloride is preferred; when P is a benzyl group, catalytic hydrogenation reduction is preferred; and when P is a p-toluenesulfonyl group, sodium hydroxide or potassium hydroxide is preferred. Compound (I) of the present invention can be further chemically modified by conventional organic chemical reactions, either by further modification of one or both of the benzene ring side chain or the pyrazole ring side chain. For example, compounds having a carboxyl group can be subjected to reactions such as esterification, amidation, and reduction to an alcohol, while compounds having an amino group can be subjected to reactions such as alkylation, acylation, and carbamate, which are easily conceivable by those skilled in the art with knowledge of organic chemistry. Furthermore, compound (I) of the present invention can also be synthesized using a 2-nitroaniline derivative (IIIc) or a nitrobenzene derivative (IIId) having a halogen or boronic acid group at the 2-position, as shown in Scheme 2. In Scheme 2, P' represents hydrogen or a suitable protecting group, X represents a halogen or a suitable boronic acid group, and Y represents the dissociated ion of the acid used in the reaction. The diazotization of the 2-nitroaniline derivative (IIIc), the reduction of the resulting diazonium compound, and the cyclization of the pyrazole ring can be synthesized according to the production methods described above in (IIIa) to (V) and (V) to (VI). The reaction from nitrobenzene derivative (IIId) to 2-nitrophenylpyrazole derivative (VIII) can be synthesized according to the methods described above for (IIIb) to (VI). Alternatively, it can be synthesized according to the method described in J. Org. Chem., vol.76, pp. 654-660, 2011. The reduction of 2-nitrophenylpyrazole derivatives (VIII) to 2-aminophenylpyrazole derivatives (IX) can be performed using catalytic hydrogenation reduction, reduction in the presence of acid, reduction with metals, or reduction with metal hydrides, as described in Experimental Chemistry Course, 4th Edition, pp. 159-266. In catalytic hydrogenation-reduction reactions, the hydrogenation pressure is typically 1 to 80 atmospheres, preferably 1 to 5 atmospheres. Suitable solvents for the above reaction vary depending on the substrate and reaction conditions, but include, but are not limited to, methanol, ethanol, methoxyethanol, ethoxyethanol, alcohols such as 1-propanol, 2-propanol, 1-butanol, 2-butanol, and 2-methyl-2-propanol; ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, methyl-t-butyl ether, diphenyl ether, diethylene glycol dimethyl ether, and 1,4-dioxane; acetic acid esters such as methyl acetate, ethyl acetate, propyl acetate, and butyl acetate; N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, glycerol, 1,3-propanediol, 1,2-dimethoxyethane, 1,2-diethoxyethane, water, and acetic acid. Furthermore, mixtures of these solvents can also be used. It is preferable to use methanol, ethanol, 2-propanol, and 1,2-dimethoxyethane. The catalysts used in catalytic hydrogenation-reduction reactions include metals such as palladium, platinum, rhodium, and nickel, as well as their complexes, and compounds of these metals or their salts adsorbed onto activated carbon. Palladium-carbon and Raney nickel are preferred. The temperature of the catalytic hydrogenation-reduction reaction described above varies depending on the type of substrate and catalyst, but is preferably between 0°C and 100°C, and more preferably between 10°C and 50°C. The catalytic hydrogenation-reduction reaction described above takes between 15 minutes and 24 hours, and is usually completed within 12 hours, although this can vary depending on the type of substrate. The substrate concentration in the above catalytic hydrogenation-reduction reaction is not particularly limited, but is usually 0.1 mM to 1 M. Preferably, it is 1 mM to 100 mM. When using metals as reducing agents, the metals used include iron, tin, and zinc, and it is necessary to add an acid to all of them. Hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, and phosphoric acid can be used as acids, but hydrochloric acid is preferred. Furthermore, these acids can also be used as solvents. The amount of metal used in the above reaction is preferably 1 to 100 equivalents, and more preferably 3 to 15 equivalents, relative to compound (VIII). Suitable solvents for the above reaction vary depending on the substrate and reaction conditions, but include, but are not limited to, water, acetic acid, methanol, ethanol, methoxyethanol, ethoxyethanol, alcohols such as 1-propanol, 2-propanol, 1-butanol, 2-butanol, and 2-methyl-2-propanol, ether solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, diphenyl ether, diethylene glycol dimethyl ether, and 1,4-dioxane, acetic acid esters such as methyl acetate, ethyl acetate, propyl acetate, and butyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, glycerol, 1,3-propanediol, 1,2-dimethoxyethane, and 1,2-diethoxyethane. Furthermore, mixtures of these solvents can also be used. Hydrochloric acid, acetic acid, ethanol, 2-propanol, and mixtures thereof are preferred. The reaction temperature described above varies depending on the type of substrate and conditions, but is preferably between 0°C and 100°C, and more preferably between 20°C and 50°C. The above reaction, while varying depending on the type of substrate and conditions, usually takes between 1 and 24 hours, and is typically completed within 12 hours. The substrate concentration in the above reaction is not particularly limited, but is usually 0.1 mM to 1 M. Preferably, it is 1 mM to 100 mM. In reduction reactions using metal hydrides, reagents such as lithium borohydride, sodium borohydride, potassium borohydride, zinc borohydride, lithium triethoxyborane, and diisobutylaluminum hydride are used, but lithium borohydride or sodium borohydride are preferred. In this case, the presence of stannous chloride or nickel(II) chloride may yield favorable results. The amount of reducing agent used in the above reaction is preferably 1 to 50 equivalents, and more preferably 1 to 5 equivalents, relative to compound (VIII). Suitable solvents for the above reaction vary depending on the type of substrate and reducing agent, but include, but are not limited to, ether-based solvents such as diethyl ether, diisopropyl ether, tetrahydrofuran, diphenyl ether, 1,4-dioxane, diethylene glycol dimethyl ether, 1,2-dimethoxyethane, and 1,2-diethoxyethane, and alcohols such as methanol, ethanol, methoxyethanol, ethoxyethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, and 2-methyl-2-propanol. Furthermore, mixtures of multiple of these solvents can also be used. Preferably, methanol and a mixture of methanol and diethylene glycol dimethyl ether are used. The reaction temperature described above varies depending on the type of substrate and conditions, but is preferably -80°C to 100°C, and more preferably -20°C to 80°C. The above reaction varies depending on the type of substrate and conditions, but it usually takes 15 minutes to 24 hours, and is often completed within 12 hours. The substrate concentration in the above reaction is not particularly limited, but is usually 0.1 mM to 1 M. Preferably, it is 1 mM to 100 mM. The obtained 2-aminophenylpyrazole derivative (IX) can be diazotized according to the method for producing (IIIa) to (IVa) described above and in accordance with Japanese Patent Application Publication No. 8-53401. The reaction from a diazonium compound to (I) can be carried out in accordance with the methods described in Japanese Patent Publication No. 8-188545 and Japanese Patent Publication No. 11-60528. The hydrolysis of the above diazonium salt can be carried out by heating under acidic conditions in water or a water-containing solvent. Suitable solvents for the above reaction vary depending on the substrate and reaction conditions, but include, but are not limited to, water, acetic acid, trifluoroacetic acid, methanol, ethanol, methoxyethanol, ethoxyethanol, glycerol, alcohols such as 1,3-propanediol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, and 2-methyl-2-propanol, ether solvents such as tetrahydrofuran, diethylene glycol dimethyl ether, 1,2-dimethoxyethane, 1,2-diethoxyethane, and 1,4-dioxane, and aprotic solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, and dimethyl sulfoxide. Furthermore, mixtures of multiple of these solvents can also be used. Water, sulfuric acid, hydrochloric acid, trifluoroacetic acid, acetic acid, methanol, ethanol, and any mixture thereof are preferred. The reaction temperature described above varies depending on the type of substrate and conditions, but is preferably 20°C to 200°C, and more preferably 50°C to 150°C. The above reaction varies depending on the type of substrate and conditions, but it usually takes 10 minutes to 24 hours, and is often completed within 12 hours. The substrate concentration in the above reaction is not particularly limited, but is usually 0.1 mM to 1 M. Preferably, it is 1 mM to 100 mM. The evaluation method is described below. (1) Measurement of antifungal activity The antifungal activity was measured using the following method. The evaluation compound was dissolved in dimethyl sulfoxide (DMSO) before use. The test medium used was RPMI1640 medium containing 0.165 M 3-morpholinopropanesulfonic acid (MOPS). Trichophyton mentagrophytes (T. mentagrophytes) ATCC18748 or Trichophyton rubrum (T. rubrum) ATCC10218 were used as test bacteria. 100 μl of the test bacterial species was dispensed at a concentration of 1 × 10⁴ conidia / ml, mixed with the evaluation compound on a 96-well half-area plate to a DMSO concentration of 1%, and cultured at a culture temperature of 28°C for 3 days (Trichophyton mentagrophytes) or 4 days (Trichophyton rubrum). Subsequently, 5 μl of Cell Counting Kit 8 (WST8) was added, and the absorbance at 450 nm and 595 nm was measured and used as the background value. Then, the cultures were incubated at 28°C for 5 hours (Trichophyton mentagrophytes) or overnight (Trichophyton rubrum) to allow color development, and the absorbance at 450 nm and 595 nm was measured again. The growth inhibition rate was calculated from the difference with the background value, and the MIC value (μg / ml) was defined as the 80% growth inhibition concentration. (2) Nail Permeability Test The evaluation compound was dissolved in a 1:1 solution of ethyl acetate and propylene glycol or in dimethyl sulfoxide at a concentration of 10 mg / ml, and 2 μl was added to a bovine nail slice placed on low-melting-point agarose. After standing in an incubator at 28°C for 5 days, the low-melting-point agarose was collected and dissolved by heating with distilled water. The concentration of the drug in the solution was quantified using high-performance liquid chromatography / mass spectrometry to determine the amount of drug that permeated the nail, and the permeability was calculated. As described in J.Pharma.Pharmacol., vol.49, pp. 866-872, 1997, there is a correlation between the drug permeability of bovine nails and human nails; therefore, in this invention, a nail permeability test was conducted using bovine nails. Furthermore, nail permeability can also be confirmed by the following methods. The evaluation compound was dissolved in an ethyl acetate:propylene glycol (1:1) solution at a concentration of 50 mg / ml. 20 μl of this solution was added to the donor side (nail plate side) of a Franz cell containing a human nail, and the cells were incubated at 37°C for at least 6 days. After 6 and 10 days of incubation, the receptor solution (phosphate buffer; pH 7.4) was sampled from the receptor chamber, and the amount of eluted drug was quantified using high-performance liquid chromatography / mass spectrometry. The present invention will be further described in detail by examples, but these examples are merely embodiments and do not limit the present invention. Also, "room temperature" in the examples usually refers to a temperature between approximately 1°C and approximately 40°C. Example 1 2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole 3.50 g of 2-methoxyphenylhydrazine hydrochloride was dissolved in 60 ml of ethanol, and 2.06 ml of acetylacetone was added and heated under reflux for 1 hour. 150 ml of water was added to the reaction mixture, neutralized with saturated sodium carbonate aqueous solution, and extracted with 150 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, the solvent was removed under reduced pressure, and the compound was purified by silica gel column chromatography (hexane:ethyl acetate = 2:1) to obtain 3.88 g of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.08(3H, s), 2.29(3H, s), 3.78(3H, s), 5.95(1H, s), 6.98-7.03(2H, m), 7.29-7.32(1H, m), 7.34-7.39(1H, m). MS(ESI); m / z 203(M+H)+ b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 3.88 g of 1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole was dissolved in 40 ml of methylene chloride, and 32 ml of 1 M methylene chloride solution of boron tribromide was added and the mixture was stirred at room temperature for 1.5 hours. The reaction mixture was added to 150 ml of water, neutralized with 1N sodium hydroxide, and extracted with 150 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, the solvent was removed under reduced pressure, and the mixture was purified by silica gel column chromatography (hexane:ethyl acetate = 3:1) to obtain 2.83 g of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.29(3H,s), 2.38(3H, s), 6.02(1H, s), 6.87-6.6.91(1H, m), 7.06-7.09(1H, m), 7.16-7.20(1H, m). MS(ESI); m / z 189(M+H)+ Example 2 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-fluorophenol a) 2-amino-4-fluorophenol 300 mg of 4-fluoro-2-nitrophenol was dissolved in 3 ml of ethanol, 120 mg of 10% palladium / carbon was added, and the mixture was stirred at room temperature for 1 hour under a hydrogen atmosphere. After filtering out the insoluble matter, the filtrate was removed under reduced pressure to obtain 211 mg of the title compound. ¹H-NMR (DMSO-d6); δ (ppm) 4.80 (2H, s), 6.09-6.14 (1H, m), 6.34-6.37 (1H, m), 6.53-6.57 (1H, m), 8.93 (1H, s). MS (FAB); m / z 128 (M+H)+ b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-fluorophenol 100 mg of 2-amino-4-fluorophenol was added to 0.8 ml of 5N hydrochloric acid, and a solution of 65 mg of sodium nitrite dissolved in 0.2 ml of water was added dropwise at 0°C, and the mixture was stirred for 30 minutes. Next, a solution of 249 mg of stannous chloride dissolved in 0.46 ml of 5N hydrochloric acid was added dropwise at 0°C, and the mixture was stirred at 0°C for 30 minutes, then at room temperature for 2 hours. The solvent was removed under reduced pressure, and 2.5 ml of ethanol and 81 μl of acetylacetone were added, and the mixture was heated under reflux for 4 hours. 50 ml of water was added to the reaction mixture, neutralized with saturated sodium bicarbonate solution, and extracted with 50 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The mixture was purified by silica gel column chromatography (hexane:ethyl acetate = 2:1) to obtain 20.6 mg of the title compound. 1H-NMR(CDCl3); δ(ppm) 2.24(3H, s), 2.33(3H, s), 5.99(1H, s), 6.82-6.90(2H, m), 6.95-6.98(1H, m). MS(FAB); m / z 207(M+H)+ Example 3 2-(1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-1H-pyrazole 200 mg of 2-methoxyphenylhydrazine hydrochloride was dissolved in 5 ml of ethanol, and 189 μl of malonaldehyde (bisdimethylacetal) was added and heated under reflux for 2 hours. 50 ml of water was added to the reaction mixture, neutralized with saturated sodium carbonate aqueous solution, and extracted with 60 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain 179.4 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 3.87(3H,s), 6.42(1H, d, J=2.4Hz), 7.02-7.07(2H, m), 7.27-7.32(1H, m), 7.68-7.72(2H, m), 8.01(1H, d, J=2.4Hz). MS(FAB); m / z 175(M+H)+ b) 121 mg of the title compound was obtained from 178 mg of 1-(2-methoxyphenyl)-1H-pyrazole using the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 6.49 (¹H, d, J=2.4Hz), 6.88-6.92 (¹H, m), 7.08-7.10 (¹H, m), 7.14-7.18 (¹H, m), 7.35-7.37 (¹H, m), 7.72 (¹H, s), 7.99 (¹H, d, J=2.4Hz). MS (ESI); m / z 161 (M+H)+ Example 4 2-(5-hydroxy-3-methyl-1H-pyrazole-1-yl)phenol a) 5-hydroxy-1-(2-methoxyphenyl)-3-methyl-1H-pyrazole 55.1 mg of the title compound was obtained from 150 mg of 2-methoxyphenylhydrazine hydrochloride and 93 μl of methyl acetoacetate in the same manner as in Example 1a). ¹H-NMR (CDCl3); δ (ppm) 2.11 (3H, s), 3.76 (3H, s), 6.88-6.94 (3H, m), 7.19-7.34 (2H, m). MS (ESI); m / z 204 (M+H)+ b) 2-(5-hydroxy-3-methyl-1H-pyrazole-1-yl)phenol 32.4 mg of the title compound was obtained from 52 mg of 5-hydroxy-1-(2-methoxyphenyl)-3-methyl-1H-pyrazole by the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 2.17 (3H, s), 5.30 (1H, s), 6.88-6.95 (2H, m), 7.15 (1H, t, J=7.6Hz), 7.37 (1H, d, J=7.6Hz). MS (FAB); m / z 191 (M+H)+ Example 5 2-(5-methyl-3-trifluoromethyl-1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-5-methyl-3-trifluoromethyl)-1H-pyrazole 300 mg of 2-methoxyphenylhydrazine hydrochloride was dissolved in 1.3 ml of 2-methoxyethanol, 2.5 ml of acetic acid and 208 μl of 1,1,1-trifluoro-2,4-pentanedione were added, and the mixture was heated under reflux for 1 hour and 40 minutes. The solvent was removed under reduced pressure, 50 ml of ethyl acetate was added, and the organic layer was washed with 50 ml of saturated sodium bicarbonate solution and 50 ml of saturated brine. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain 485.6 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.14(3H, s), 3.78(3H, s), 6.40(1H, s), 7.00-7.07(2H, m), 7.31-7.33(1H, m), 7.41-7.45(1H, m). MS(ESI); m / z 257(M+H)+ b) 320.1 mg of the title compound was obtained from 2-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)phenol 1-(2-methoxyphenyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazole by the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 2.41 (3H, s), 6.52 (1H, s), 6.95-6.99 (1H, m), 7.11-7.13 (1H, m), 7.20-7.24 (1H, m), 7.28-7.32 (1H, m). MS (FAB); m / z 243 (M+H)+ Example 6 2-(3,5-bistrifluoromethyl-1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-3,5-bistrifluoromethyl)-1H-pyrazole The title compound was obtained from 300 mg of 2-methoxyphenylhydrazine hydrochloride and 243 μl of hexafluoroacetylacetone in the same manner as in Example 5a). ¹H-NMR (CDCl3); δ (ppm) 3.77 (3H, s), 7.01-7.06 (3H, m), 7.33 (1H, d, J=7.6Hz), 7.49 (1H, d, J=7.6Hz). MS (ESI); m / z 311 (M+H)+ b) 2-(3,5-bistrifluoromethyl)-1H-pyrazole-1-yl)phenol 455.6 mg of the title compound was obtained from 1-(2-methoxyphenyl)-3,5-bistrifluoromethyl)-1H-pyrazole obtained in a) above by the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 6.99-7.04 (¹H, m), 7.07-7.08 (¹H, m), 7.10 (¹H, s), 7.32-7.41 (²H, m). MS (FAB); m / z 297 (M+H)+ Example 7 2-(3-methyl-1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-3-methyl-1H-pyrazole 115.1 mg of the title compound was obtained from 200 mg of 2-methoxyphenylhydrazine hydrochloride and 151 μl of 4,4-dimethoxybutan-2-one by the same method as in Example 1a). ¹H-NMR (CDCl3); δ (ppm) 2.31 (3H, s), 3.80 (3H, s), 6.14 (1H, d, J=2.4Hz), 6.95-6.99 (2H, m), 7.18-7.22 (1H, m), 7.61-7.63 (1H, m), 7.84 (1H, d, J=2.4Hz). MS (FAB); m / z 189 (M+H)+ b) 76 mg of the title compound was obtained from 115 mg of 1-(2-methoxyphenyl)-3-methyl-1H-pyrazole using the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 2.36 (3H, s), 6.24 (1H, d, J=2.4Hz), 6.85-6.89 (1H, m), 7.05-7.14 (2H, m), 7.29-7.31 (1H, m), 7.86 (1H, d, J=2.4Hz). MS (FAB); m / z 175 (M+H)+ Example 8 2-(5-methyl-1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-5-methyl-1H-pyrazole 70 mg of the title compound was obtained from 200 mg of 2-methoxyphenylhydrazine hydrochloride and 151 μl of 4,4-dimethoxybutan-2-one in the same manner as in Example 1a). ¹H-NMR (CDCl3); δ (ppm) 2.07 (3H, s), 3.71 (3H, s), 6.09 (1H, s), 6.94-6.99 (2H, m), 7.24-7.26 (1H, m), 7.31-7.35 (1H, m), 7.52 (1H, s). MS (FAB); m / z 189 (M+H)+ b) 2-(5-methyl-1H-pyrazole-1-yl)phenol 45.5 mg of the title compound was obtained from 69 mg of 1-(2-methoxyphenyl)-5-methyl-1H-pyrazole by the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 2.41 (3H, s), 6.27 (1H, d, J=1.6Hz), 6.90-6.94 (1H, m), 7.10-7.12 (1H, m), 7.19-7.24 (2H, m), 7.66 (1H, d, J=1.6Hz). MS (FAB); m / z 175 (M+H)+ Example 9 2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol a) 1-(2-methoxyphenyl)-3,4,5-trimethyl-1H-pyrazole 200 mg of 2-methoxyphenylhydrazine hydrochloride was dissolved in 4 ml of ethanol, and 134 μl of 3-methyl-2,4-pentanedione was added and the mixture was heated under reflux for 3 hours. 50 ml of water was added to the reaction mixture, neutralized with saturated sodium carbonate aqueous solution, and extracted with 60 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain 209.8 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 1.98(3H, s), 2.02(3H, s), 2.24(3H, s), 3.80(3H, s), 6.99-7.04(2H, m), 7.29-7.31(1H, m), 7.34-7.39(1H, m). MS(FAB); m / z 217(M+H)+ b) 2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 104 mg of the title compound was obtained from 209 mg of 1-(2-methoxyphenyl)-3,4,5-trimethyl-1H-pyrazole by the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 1.99 (3H, s), 2.25 (3H, s), 2.31 (3H, s), 6.90 (1H, t, J=8.0Hz), 7.08 (1H, d, J=8.0Hz), 7.06-7.20 (2H, m), 9.89 (1H, s). MS (ESI); m / z 203 (M+H)+ Example 10 2-(5-amino-3-tert-butyl-1H-pyrazole-1-yl)phenol a) 3-tert-butyl-1-(2-methoxyphenyl)-1H-pyrazole-5-amine 310.3 mg of the title compound was obtained from 300 mg of 2-methoxyphenylhydrazine hydrochloride, 215 mg of 4,4-dimethyl-3-oxopentannitrile, and 40 μl of acetic acid in the same manner as in Example 1a). 1H-NMR(CDCl3);δ(ppm) 1.32(9H, s), 3.80(2H, s), 3.86(3H, s), 5.51(1H, s), 7.01-7.08(2H, m), 7.30-7.35(1H, m), 7.45-7.47(1H, m). MS(FAB); m / z 246(M+H)+ b) 66.2 mg of the title compound was obtained from 100 mg of 2-(5-amino-3-tert-butyl-1H-pyrazole-1-yl)phenol 3-tert-butyl-1-(2-methoxyphenyl)-1H-pyrazole-5-amine by the same method as in Example 1b). 1H-NMR(CDCl3);δ(ppm) 1.30(9H, s), 3.93(2H, s), 5.55(1H, s), 6.90(1H, dt, J=1.6, 8.0Hz), 7.08(1H, dd, J=1.6, 8.0Hz), 7.17(1H, dt, J=1.6, 8.0Hz), 7.47(1H, dd, J=1.6, 8.0Hz), 10.39(1H, brs). MS(FAB); m / z 232(M+H)+ Example 11 4-Chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 1-(5-chloro-2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole 104.8 mg of the title compound was obtained from 388 mg of 5-chloro-2-methoxyaniline hydrochloride by the same method as in 2b). ¹H-NMR (CDCl3); δ (ppm) 2.11 (3H, s), 2.29 (3H, s), 3.79 (3H, s), 5.96 (1H, s), 6.93 (1H, dd, J=2.4, 7.2Hz), 7.33-7.35 (2H, m). MS (FAB); m / z 237 (M+H)+ b) 67.3 mg of the title compound was obtained from 104.8 mg of 1-(5-chloro-2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole using the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 2.30 (3H, s), 2.43 (3H, s), 6.05 (1H, s), 7.02 (1H, d, J=8.8Hz), 7.14-7.20 (2H, m), 10.08 (1H, s). MS (FAB); m / z 223 (M+H)+ Example 12 2-Chloro-6-(3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 1-(3-chloro-2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole 30.6 mg of the title compound was obtained from 158 mg of 3-chloro-o-anisidine by the same method as in Example 2b). ¹H-NMR (CDCl3); δ (ppm) 2.14 (3H, s), 2.29 (3H, s), 3.49 (3H, s), 5.99 (1H, s), 7.12 (1H, t, J=8.0Hz), 7.27-7.31 (1H, m), 7.43-7.46 (1H, m). MS (ESI); m / z 236 (M+H)+ b) 2-Chloro-6-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 27.4 mg of the title compound was obtained from 63.4 mg of 1-(3-chloro-2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 2.30 (3H, s), 2.40 (3H, s), 6.05 (1H, s), 6.86 (1H, t, J=8.0Hz), 7.13-7.15 (1H, m), 7.26-7.31 (1H, m), 10.66 (1H, s). MS (FAB); m / z 223 (M+H)+ Example 13 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 193.9 mg of the title compound was obtained from 174.6 mg of 2-methoxyphenylhydrazine hydrochloride and 114 μl of 3-chloropentan-2,4-dione by the same method as in Example 1a). ¹H-NMR (CDCl3); δ (ppm) 2.09 (3H, s), 2.29 (3H, s), 3.81 (3H, s), 7.00-7.06 (2H, m), 7.30 (1H, dd, J=1.6, 7.6Hz), 7.38-7.43 (1H, m). MS (FAB); m / z 237 (M+H)+ b) 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol 151.9 mg of the title compound was obtained from 193 mg of 4-chloro-1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 2.30 (3H, s), 2.37 (3H, s), 6.91-6.95 (1H, m), 7.09 (1H, dd, J=1.6, 8.0 Hz), 7.17 (1H, dd, J=1.6, 8.0 Hz), 7.21-7.25 (1H, m), 9.23 (1H, s). MS (FAB); m / z 223 (M+H)+ Example 14 2-(3,5-diethyl-1H-pyrazole-1-yl)phenol a) 3,5-diethyl-1-(2-methoxyphenyl)-1H-pyrazole 209.8 mg of the title compound was obtained from 174.6 mg of 2-methoxyphenylhydrazine hydrochloride and 135.5 μl of 3,5-heptanedione by the same method as in Example 1a). 1H-NMR(CDCl3);δ(ppm) 1.14-1.18(3H, m), 1.25-1.31(3H, m), 2.42(2H, q, J=7.2Hz), 2.67-2.73(2H, m), 3.78(3H, s), 6.03(1H, s), 6.99-7.04(2H, m), 7.31-7.40(2H, m). MS(FAB); m / z 231(M+H)+ b) 2-(3,5-diethyl-1H-pyrazole-1-yl)phenol 159.2 mg of the title compound was obtained from 207 mg of 3,5-diethyl-1-(2-methoxyphenyl)-1H-pyrazole by the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 1.24-1.31 (6H, m), 2.69 (2H, q, J=7.6Hz), 2.76 (2H, q, J=7.6Hz), 6.11 (1H, s), 6.90 (1H, q, J=7.6Hz), 7.09 (1H, d, J=7.6Hz), 7.19-7.22 (2H, m), 9.69 (1H, s). MS (FAB); m / z 217 (M+H)+ Example 15 3-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,2-diol a) 1-(2,3-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole 189 mg of the title compound was obtained from 306 mg of 2,3-dimethoxyaniline by the same method as in Example 2b). ¹H-NMR (CDCl3); δ (ppm) 2.14 (3H, s), 2.29 (3H, s), 3.53 (3H, s), 3.91 (3H, s), 5.96 (1H, s), 6.96-6.70 (2H, m), 7.12 (1H, t, J=8.0Hz). MS (FAB); m / z 233 (M+H)+ b) 3-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,2-diol 28.9 mg of the title compound was obtained from 186 mg of 1-(2,3-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 2.26 (3H, s), 2.38 (3H, s), 5.99 (1H, s), 6.75-6.85 (3H, m). MS (FAB); m / z 205 (M+H)+ Example 16: 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,4-diol a) 1-(2,5-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole 260.3 mg of the title compound was obtained from 306 mg of 2,5-dimethoxyaniline by the same method as in Example 2b). ¹H-NMR (CDCl3); δ (ppm) 2.11 (3H, s), 2.30 (3H, s), 3.73 (3H, s), 3.78 (3H, s), 5.96 (1H, s), 6.91-6.93 (3H, m). b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,4-diol 162.6 mg of the title compound was obtained from 260.3 mg of 1-(2,5-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Example 1b). ¹H-NMR (DMSO-d6); δ (ppm) 2.07 (3H, s), 2.14 (3H, s), 5.93 (1H, s), 6.56 (1H, d, J=2.8Hz), 6.66-6.69 (1H, m), 6.80 (1H, d, J=8.8Hz), 9.02 (1H, s), 9.17 (1H, s). MS (FAB); m / z 205 (M+H)+ Example 17 2-(4-ethyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 4-ethyl-1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole 236.6 mg of the title compound was obtained from 200 mg of 2-methoxyphenylhydrazine hydrochloride and 155 μl of 3-ethyl-2,4-pentanedione by the same method as in Example 1a). 1H-NMR(CDCl3);δ(ppm) 1.13(3H, t, J=7.6Hz), 2.03(3H, s), 2.27(3H, s), 2.42(2H, q, J=7.6Hz), 3.79(3H, s), 6.99-7.04(2H, m), 7.30-7.39(2H, m). MS(FAB); m / z 231(M+H)+ b) 2-(4-ethyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol 196.2 mg of the title compound was obtained from 232 mg of 4-ethyl-1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 1.12 (3H, t, J=7.6Hz), 2.27 (3H, s), 2.33 (3H, s), 2.43 (2H, q, J=7.6Hz), 6.88-6.92 (1H, m), 7.08-7.10 (1H, m), 7.06-7.19 (2H, m), 9.90 (1H, s). MS (FAB); m / z 217 (M+H)+ Example 18 5-Fluoro-2-(3,4,5,-trimethyl-1H-pyrazole-1-yl)phenol 114.7 mg of the title compound was obtained from 201.2 mg of 2-amino-5-fluorophenol and 184 μl of 3-methyl-2,4-pentanedione by the same method as in Example 1b). ¹H-NMR (CDCl3); δ (ppm) 1.99 (3H, s), 2.23 (3H, s), 2.28 (3H, s), 6.59-6.64 (1H, m), 6.78-6.81 (1H, m), 7.10-7.14 (1H, m). MS (ESI); m / z 221 (M+H)+ Example 19 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,4-diol a) 4-chloro-1-(2,5-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole 333.7 mg of the title compound was obtained from 306 mg of 2,5-dimethoxyaniline and 228 μl of 3-chloropentan-2,4-dione by the same method as in Example 2b). ¹H-NMR (CDCl3); δ (ppm) 2.10 (3H, s), 2.29 (3H, s), 3.74 (3H, s), 3.78 (3H, s), 6.94-6.97 (2H, m), 7.26 (1H, s). MS (FAB); m / z 267 (M+H)+ b) 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,4-diol 184.8 mg of the title compound was obtained from 329 mg of 4-chloro-1-(2,5-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Example 1b). ¹H-NMR (DMSO-d6); δ (ppm) 2.05 (3H, s), 2.15 (3H, s), 6.58 (1H, d, J=2.8Hz), 6.72 (1H, dd, J=2.8, 8.8Hz), 6.82 (1H, d, J=8.8Hz), 9.11 (1H, s), 9.33 (1H, s). MS (FAB); m / z 239 (M+H)+ Example 20: 4-Fluoro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol. 84.8 mg of the title compound was obtained from 111 mg of 2-amino-4-fluorophenol and 102 μl of 3-methyl-2,4-pentanedione by the same method as in Example 2b). ¹H-NMR (CDCl3); δ (ppm): 1.99 (3H, s), 2.23 (3H, s), 2.24 (3H, s), 2.34 (3H, s), 6.87-6.95 (2H, m), 7.00-7.03 (1H, m), 9.90 (1H, s). MS (FAB); m / z: 221 (M+H)+ Example 21 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol 62 mg of the title compound was obtained from 100 mg of 2-amino-5-fluorophenol and 90 μl of 3-chloropentan-2,4-dione by the same method as in Example 2b). ¹H-NMR (CDCl3); δ (ppm) 2.29 (3H, s), 2.35 (3H, s), 6.62-6.67 (1H, m), 6.78-6.81 (1H, m), 7.10-7.14 (1H, m), 9.44 (1H, s). MS (FAB); m / z 241 (M+H)+ Example 22 1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate ethyl a) 1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate 82.6 mg of the title compound was obtained from 175 mg of 2-methoxyphenylhydrazine hydrochloride and 156 μl of ethyl 2-acetyl-3-oxobutanoate in the same manner as in Example 1a). 1H-NMR(CDCl3);δ(ppm) 1.38(3H, t, J=7.6Hz), 2.33(3H, s), 2.50(3H, s), .80(3H, s), 4.32(2H, q, J=7.6Hz), 7.02-7.08(2H, m), 7.30-7.32(1H, m), 7.41-7.45(1H, m). MS(ESI); m / z 275(M+H)+ b) 1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate ethyl 1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate 21 mg of the title compound was obtained from 82 mg of ethyl 1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate by the same method as in Example 1b). 1H-NMR(CDCl3);δ(ppm) 1.39(3H, t, J=7.2Hz), 2.50(3H, s), 2.61(3H, s), 4.34(2H, q, J=7.2Hz), 6.96(1H, t, J=8.4Hz), 7.10(1H, d, MS(FAB); m / z 261(M+H)+ Example 23 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propanoate methyl a) 3-(1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propanoate 96 mg of the title compound was obtained from 174.6 mg of 2-methoxyphenylhydrazine hydrochloride and 175 μl of methyl 4-acetyl-5-oxohexanoate by the same method as in Example 1a). 1H-NMR(CDCl3);δ(ppm) 2.04(3H, s), 2.27(3H, s), 2.49-2.54(2H, m), 2.74-2.78(2H, m), 3.68(3H, s), 3.79(3H, s), 6.99-7.02(2H, m), 7.28-7.31(1H, m), 7.35-7.39(1H, m). MS(FAB); m / z 289(M+H)+ b) 36.8 mg of the title compound was obtained from 96 mg of methyl 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propanoate by the same method as in Example 1b). 1H-NMR(CDCl3);δ(ppm) 2.28(3H, s), 2.34(3H, s), 2.51(2H, t, J=8.0Hz), 2.77(2H, t, J=8.0Hz), 3.69(3H, s), 6.91(1H, t, J=6.8Hz), 7.08-7.10(1H, m), 7.17-7.26(2H, m), 9.73(1H, s). MS(ESI); m / z 275(M+H)+ Example 24 2-(4-butyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 4-butyl-1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole 273 mg of the title compound was obtained from 175 mg of 2-methoxyphenylhydrazine hydrochloride and 168 μl of 3-n-butyl 2,4-pentanedione in the same manner as in Example 1a). 1H-NMR(CDCl3);δ(ppm) 0.94(3H, t, J=7.2Hz), 1.32-1.39(2H, m), 1.45-1.50(2H, m), 2.01(3H, m), 2.26(3H, s), 2.39(2H, q, J=7.2Hz), 3.79(3H, s), 6.99-7.04(2H, m), 7.30-7.38(2H, m). MS(FAB); m / z 259(M+H)+ b) 2-(4-butyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol 208.8 mg of the title compound was obtained from 273 mg of 4-butyl-1-(2-methoxyphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Example 1b). 1H-NMR(CDCl3);δ(ppm) 0.95(3H, t, J=7.6Hz), 1.33-1.39(2H, m), 1.43-1.48(2H, m), 2.26(3H, s), 2.32(3H, s), 2.40(2H, t, J=7.6Hz), 6.88-6.92(1H, m), 7.08(1H, d, J=8.4Hz), 7.16-7.20(2H, m), 9.93(1H, s). MS(FAB); m / z 245(M+H)+ Example 25 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol a) 2-amino-5-fluorophenol 252.5 mg of the title compound was obtained from 314 mg of 5-fluoro-2-nitrophenol by the same method as in Example 2a). ¹H-NMR (DMSO-d6); δ (ppm) 6.33-6.38 (¹H, m), 6.45-6.48 (¹H, m), 6.51-6.55 (¹H, m). MS (FAB); m / z 128 (M+H)+ b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol 89.6 mg of the title compound was obtained from 150 mg of 2-amino-5-fluorophenol by the same method as in Example 2b). ¹H-NMR (CDCl3); δ (ppm) 2.29 (3H, s), 2.37 (3H, s), 6.03 (1H, s), 6.60-6.65 (1H, m), 6.78-6.81 (1H, m), 7.13-7.16 (1H, m). MS (ESI); m / z 207 (M+H)+ Example 26 5-Chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 168.8 mg of the title compound was obtained from 287 mg of 2-amino-5-chlorophenol by the same method as in Example 2b). ¹H-NMR (CDCl3); δ (ppm) 2.30 (3H, s), 2.40 (3H, s), 6.05 (1H, s), 6.87-6.90 (1H, m), 7.10-7.14 (2H, m), 10.23 (1H, s). MS (FAB); m / z 223 (M+H)+ Example 27 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-nitrophenol 75.4 mg of the title compound was obtained from 308 mg of 2-amino-3-nitrophenol by the same method as in Example 2b). ¹H-NMR (CD3OD); δ (ppm) 2.14 (3H, s), 2.19 (3H, s), 6.04 (1H, s), 7.27 (1H, dd, J=1.6, 7.6Hz), 7.44 (1H, dd, J=1.6, 7.6Hz), 7.50 (1H, t, J=7.6Hz). MS (FAB); m / z 234 (M+H)+ Example 28 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-nitrophenol 101 mg of the title compound was obtained from 308 mg of 2-amino-5-nitrophenol by the same method as in Example 2b). ¹H-NMR (CDCl3); δ (ppm) 2.33 (3H, s), 2.50 (3H, s), 6.13 (1H, s), 7.38 (1H, d, J=7.6Hz), 7.79-7.81 (1H, m), 7.95 (1H, s). MS (ESI); m / z 234 (M+H)+ Example 29 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propionic acid 29.9 mg of methyl 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propanoate was dissolved in 0.6 ml of methanol, and 0.29 ml of 1N sodium hydroxide was added and the mixture was stirred at room temperature for 3.5 hours. 20 ml of water was added to the reaction mixture, neutralized with 1N hydrochloric acid, and extracted with 20 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain 7.5 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.29(3H, s), 2.34(3H, s), 2.56(2H, t, J=7.6Hz), 2.78(2H, t, J=7.6Hz), 6.89-6.93(1H, m), 7.08-7.10(1H, m), 7.16-7.22(2H, m). MS(FAB); m / z 261(M+H)+ Example 30 5-Chloro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 152 mg of the title compound was obtained from 287 mg of 2-amino-5-chlorophenol and 233 μl of 3-methyl-2,4-pentanedione by the same method as in Example 2b). ¹H-NMR (CDCl3); δ (ppm) 1.99 (3H, s), 2.24 (3H, s), 2.31 (3H, s), 6.86-6.89 (1H, m), 7.09-7.11 (2H, m). MS (FAB); m / z 227 (M+H)+ Example 31 5-amino-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 86 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-nitrophenol was dissolved in 1.7 ml of ethanol, 43 mg of 10% palladium / carbon was added, and the mixture was stirred at room temperature for 45 minutes under a hydrogen atmosphere. After filtering out the insoluble matter, the solvent was removed under reduced pressure to obtain 30.4 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.28(3H, s), 2.33(3H, s), 3.72(2H, s), 5.99(1H, s), 6.22(1H, dd, J=2.4, 8.4Hz), 6.40(1H, d, J=2.4Hz), 6.97(1H, d, J=8.4Hz), 9.27(1H, s). MS(FAB); m / z 204(M+H)+ Example 32 5-Nitro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 289.5 mg of the title compound was obtained from 308 mg of 2-amino-5-nitrophenol and 233 μl of 3-methyl-2,4-pentanedione by the same method as in Example 2b). ¹H-NMR (CDCl3); δ (ppm) 2.02 (3H, s), 2.24 (3H, s), 2.40 (3H, s), 7.33 (1H, d, J=8.8Hz), 7.79 (1H, dd, J=2.4, 8.8Hz), 7.94 (1H, d, J=2.4Hz). MS (FAB); m / z 248 (M+H)+ Example 33 4-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol a) 2,4-dimethoxyphenylboronic acid 576 μl of 1-bromo-2,4-dimethoxybenzene was dissolved in 5.8 ml of tetrahydrofuran, and 3 ml of 1.6 mol / l n-butyllithium hexane solution was added dropwise under an argon atmosphere at -78°C. Then, 1.1 ml of triisopropyl borate was added, and the mixture was stirred at -78°C for 40 minutes, followed by stirring at room temperature for 2 hours. 40 ml of water and 1 ml of 5N hydrochloric acid were added to the reaction mixture, and the mixture was extracted with 50 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified by silica gel column chromatography (hexane:ethyl acetate = 2:1) to obtain 610.2 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 3.85(3H, s), 3.89(3H, s), 5.81(2H, s), 6.46(1H, s), 6.56(1H, dd, J=2.0, 8.4Hz), 7.77(1H, d, J=8.4Hz). b) 1-(2,4-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole 610.2 mg of 2,4-dimethoxyphenylboronic acid was dissolved in 6 ml of methylene chloride, and 387 mg of 3,5-dimethylpyrazole, 730 mg of copper(II) acetate, and 948 μl of pyridine were added. The mixture was stirred overnight at room temperature. 60 ml of water was added to the reaction mixture, and it was extracted with 60 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified by silica gel column chromatography (hexane:ethyl acetate = 3:2) to obtain 81.7 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.07(3H, s), 2.29(3H, s), 3.77(3H, s), 3.85(3H, s), 5.94(1H, s), 6.52-6.54(2H, m), 7.22-7.24(1H, m). MS(FAB); m / z 233(M+H)+ c) 118.4 mg of 4-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol 1-(2,4-dimethoxyphenyl)-3,5-dimethyl-1H-pyrazole was dissolved in 2.3 ml of methylene chloride, and 1.7 ml of 1 M boron tribromide solution in methylene chloride was added and the mixture was stirred at room temperature for 1 hour. The reaction mixture was added to 30 ml of water, neutralized with 1N sodium hydroxide, and extracted with 50 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, the solvent was removed under reduced pressure, and the compound was purified using preparative thin-layer silica gel column chromatography (hexane:ethyl acetate = 1:2) to obtain 71.7 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.29(3H, s), 2.33(3H,s), 6.01(1H, s), 6.37(1H, dd, J=2.8, 8.8Hz), 6.53(1H, d, J=2.8Hz), 7.03(1H, d, J=8.8Hz). MS(ESI); m / z 205(M+H)+ Example 34: 5-amino-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol. 118.4 mg of the title compound was obtained from 200 mg of 5-nitro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol using the same method as in Example 31. ¹H-NMR (CDCl3); δ (ppm): 1.97 (3H, s), 2.23 (3H, s), 2.24 (3H, s), 3.70 (2H, s), 6.22 (1H, dd, J=2.4, 8.4Hz), 6.40 (1H, d, J=2.4Hz), 6.95 (1H, d, J=8.4Hz), 9.34 (1H, s). MS (FAB); m / z: 218 (M+H)+ Example 35 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylate 239.4 mg of the title compound was obtained from 334 mg of methyl 4-amino-3-hydroxybenzenecarboxylate by the same method as in Example 2b). ¹H-NMR (CDCl3); δ (ppm) 2.31 (3H, s), 2.45 (3H, s), 3.92 (3H, s), 6.08 (1H, s), 7.26-7.29 (1H, m), 7.60 (1H, dd, J=1.6, 8.0 Hz), 7.76 (1H, d, J=1.6 Hz). MS (ESI); m / z 247 (M+H)+ Example 36 3-amino-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 38.9 mg of the title compound was obtained from 56.6 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-nitrophenol by the same method as in Example 31. ¹H-NMR (CDCl3); δ (ppm) 2.14 (3H, s), 2.25 (3H, s), 3.57 (2H, s), 6.02 (1H, s), 6.32-6.37 (2H, m), 7.02 (1H, t, J=8.0Hz). MS (FAB); m / z 204 (M+H)+ Example 37 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylic acid 100 mg of methyl 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylic acid was dissolved in 1 ml of methanol, and 1.6 ml of 1N sodium hydroxide was added and the mixture was stirred at room temperature for 3.5 hours. 20 ml of water was added to the reaction mixture, neutralized with 1N hydrochloric acid, and extracted with 20 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain 40.8 mg of the title compound. 1H-NMR(CD3OD);δ(ppm) 2.16(3H, s), 2.24(3H, s), 6.04(1H, s), 7.30(1H, d, J=8.4Hz), 7.59(1H, dd, J=2.0, 8.4Hz), 7.64(1H, d, J=2.0Hz). MS(ESI); m / z 233(M+H)+ Example 38 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxy-N,N-dimethylbenzamide 36 mg of 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylic acid was dissolved in 0.4 ml of dimethylformamide, and 36 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 25 mg of 1-hydroxybenzotriazole, and 93 μl of dimethylamine (2.0 M THF solution) were added and the mixture was stirred at room temperature for 4 hours. 10 ml of water was added to the reaction mixture and extracted with 15 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified by preparative thin-layer silica gel column chromatography (ethyl acetate) to obtain 11.4 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.31(3H, s), 2.41(3H, s), 3.02(3H, s), 3.11(3H, s), 6.06(1H, s), 6.97(1H, d, J=8.0Hz), 7.23(1H, d, J=8.0Hz), 7.26(1H, s). MS(ESI); m / z 259(M+H)+ Example 39 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzamide 34.3 mg of the title compound was obtained from 73.1 mg of 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylic acid and 38 μl of aqueous ammonia by the same method as in Example 38. ¹H-NMR (CD3OD); δ (ppm) 2.16 (3H, s), 2.24 (3H, s), 6.04 (1H, s), 7.29 (1H, d, J=8.4Hz), 7.41 (1H, dd, J=2.0, 8.4Hz), 7.50 (1H, d, J=2.0Hz). MS (ESI); m / z 232 (M+H)+ Example 40 3-Hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzenecarboxylic acid a) 3-Hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzenecarboxylic acid 110.4 mg of the title compound was obtained from 167 mg of methyl 4-amino-3-hydroxybenzenecarboxylic acid and 116 μl of 3-methyl-2,4-pentanedione in the same manner as in Example 2b). 1H-NMR(CDCl3);δ(ppm) 2.00(3H, s), 2.26(3H, s), 2.36(3H, s), 3.92(3H, s), 7.23-7.26(1H, m), 7.58-7.60(1H, m), 7.49(1H, s), 10.53(1H, s). MS(ESI); m / z 261(M+H)+ b) 3-Hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzenecarboxylic acid 68.7 mg of the title compound was obtained from 110 mg of methyl 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzenecarboxylic acid by the same method as in Example 37. ¹H-NMR (CD3OD); δ (ppm) 1.99 (3H, s), 2.09 (3H, s), 2.20 (3H, s), 7.28 (1H, d, J=8.0Hz), 7.59 (1H, dd, J=2.0, 8.0Hz), 7.63 (1H, d, J=2.0Hz). MS (ESI); m / z 247 (M+H)+ Example 41 3-Hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzamide 33.3 mg of the title compound was obtained from 65 mg of 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzenecarboxylic acid and 32 μl of aqueous ammonia by the same method as in Example 38. ¹H-NMR (CD3OD); δ (ppm) 1.99 (3H, s), 2.09 (3H, s), 2.19 (3H, s), 7.27 (1H, d, J=8.0Hz), 7.40 (1H, dd, J=2.0, 8.0Hz), 7.57 (1H, d, J=2.0Hz). MS (ESI); m / z 246 (M+H)+ Example 42 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzamide a) 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzoate methyl 4-amino-3-hydroxybenzoate 69.1 mg of the title compound was obtained from 167 mg of methyl 4-amino-3-hydroxybenzoate and 114 μl of 3-chloropentan-2,4-dione by the same method as in Example 2b). ¹H-NMR (CDCl3); δ (ppm) 2.32 (3H, s), 2.42 (3H, s), 3.93 (3H, s), 7.24-7.26 (1H, m), 7.60-7.66 (1H, m), 7.77 (1H, s). b) 39.2 mg of the title compound was obtained from 9.1 mg of 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzoic acid methyl 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzoic acid 6 by the same method as in Example 37. ¹H-NMR (CD3OD); δ (ppm) 2.15 (3H, s), 2.24 (3H, s), 7.32-7.35 (1H, m), 7.59-7.66 (2H, m). MS (ESI); m / z 267 (M+H)+ c) 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzamide 12.3 mg of the title compound was obtained from 37.9 mg of 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzoic acid and 1.7 μl of aqueous ammonia by the same method as in Example 38. ¹H-NMR (CD3OD); δ (ppm) 2.14 (3H, s), 2.24 (3H, s), 7.29-7.32 (1H, m), 7.41-7.44 (1H, m), 7.50 (1H, s). MS (ESI); m / z 266 (M+H)+ Example 43 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol a) 2-aminobenzene-1,3-diol 465 mg of 2-nitroresorcinol was dissolved in 9.3 ml of ethanol, 230 mg of 10% palladium / carbon was added, and the mixture was stirred at room temperature for 1 hour under a hydrogen atmosphere. After filtering out the insoluble matter, the solvent was removed under reduced pressure to obtain 338.5 mg of the title compound. ¹H-NMR (DMSO-d6); δ (ppm) 6.20-6.28 (3H, m). MS (ESI); m / z 126 (M+H)+ b) 2-amino-1,3-phenylene bis(4-methylbenzenesulfonate) 100 mg of 2-aminobenzene-1,3-diol was dissolved in 2 ml of dichloromethane, and 234 μl of triethylamine and 320 mg of p-toluenesulfonyl chloride were added. The mixture was stirred at room temperature for 1.5 hours. 20 ml of water was added to the reaction mixture and extracted with 20 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified by silica gel column chromatography (hexane:ethyl acetate = 4:1) to obtain 278.1 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.46(6H, s), 3.83(2H, s), 6.48(1H, t, J=8.1Hz), 6.79(2H, d, J=8.3Hz), 7.32(4H, d, J=8.1Hz), 7.72(4H, d, J=8.3Hz). MS(ESI); m / z 434(M+H)+ c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl 4-methylbenzenesulfonate 2-amino-1,3-phenylene bis(4-methylbenzenesulfonate) 278 mg was added to 0.64 ml of 5N hydrochloric acid, and a solution of 58 mg of sodium nitrite dissolved in 0.4 ml of water was added dropwise at 0°C, and the mixture was stirred for 30 minutes. Next, a solution of 289 mg of stannous chloride dissolved in 0.32 ml of 5N hydrochloric acid was added dropwise at 0°C, and the mixture was stirred for 1 hour. The solvent was removed under reduced pressure, and 1.3 ml of ethanol and 66 μl of acetylacetone were added, and the mixture was heated under reflux for 2 hours. 50 ml of water was added to the reaction mixture, neutralized with saturated sodium bicarbonate solution, and extracted with 50 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified by silica gel column chromatography (hexane:ethyl acetate = 4:1 to 1:1) to obtain 62.9 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.15(3H, s), 2.17(3H, s), 2.41(3H, s), 5.91(1H, s), 6.93-6.-96(2H, m), 7.14(2H, d, J=8.0Hz), 7.18-7.26(1H, m), 7.35(2H, d, J=8.0Hz). MS(ESI); m / z 359(M+H)+ d) 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl 62 mg of 4-methylbenzene sulfonate was mixed with a solution of 97 mg of potassium hydroxide dissolved in 1.5 ml of ethanol and 1.5 ml of water, and the mixture was heated under reflux for 3.5 hours. 20 ml of water was added to the reaction mixture, and it was extracted with 20 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The mixture was purified using preparative thin-layer silica gel column chromatography (hexane:ethyl acetate = 1:1) to obtain 20.8 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.15(3H, s), 2.16(3H, s), 5.98(1H, s), 6.45(2H, d, J=8.4Hz), 7.00(1H, t, J=8.4Hz). MS(ESI); m / z 205(M+H)+ Example 44 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol a) 2-amino-5-methylphenyl 4-methylbenzenesulfonate 400 mg of 2-amino-5-methylphenol was dissolved in 6.5 ml of dichloromethane, and 476 μl of triethylamine and 619 mg of p-toluenesulfonyl chloride were added. The mixture was stirred at room temperature for 1 hour. 60 ml of water was added to the reaction mixture and extracted with 60 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified by silica gel column chromatography (hexane:ethyl acetate = 3:1) to obtain 730.1 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.15(3H, s), 2.46(3H, s), 3.63(2H, brs), 6.61-6.63(1H, m), 6.67(1H, s), 6.82-6.85(1H, m), 6.33(2H, d, J=8.4Hz), 7.78(2H, d, J=8.4Hz).MS(ESI); m / z 278(M+H)+ b) 453 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenyl 4-methylbenzenesulfonate and 2-amino-5-methylphenyl 4-methylbenzenesulfonate were added to 1.6 ml of 5N hydrochloric acid, and a solution of 146 mg of sodium nitrite dissolved in 1 ml of water was added dropwise at 0°C, and the mixture was stirred for 30 minutes. Next, a solution of 736 mg of stannous chloride dissolved in 0.8 ml of 5N hydrochloric acid was added dropwise at 0°C, and the mixture was stirred for 1 hour. The solvent was removed under reduced pressure, and 3.2 ml of ethanol and 167 μl of acetylacetone were added, and the mixture was heated under reflux for 2 hours. 50 ml of water was added to the reaction mixture, neutralized with saturated sodium bicarbonate solution, and extracted with 80 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified by silica gel column chromatography (hexane:ethyl acetate = 2:1) to obtain 199.6 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.09(3H, s), 2.11(3H, s), 2.41(3H,s), 2.43(3H, s), 5.82(1H, s), 7.15-7.21(4H, m), 7.36-7.38(3H, m). MS(ESI); m / z 357(M+H)+ c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenyl A solution of 314 mg of potassium hydroxide dissolved in 4 ml of ethanol and 4 ml of water was added to 199.6 mg of 4-methylbenzenesulfonate and heated under reflux for 1 hour. 20 ml of water was added to the reaction mixture and extracted with 20 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, the solvent was removed under reduced pressure, and the mixture was purified using preparative thin-layer silica gel column chromatography (hexane:ethyl acetate = 4:1). The desired fraction was dissolved in 1,4-dioxane and freeze-dried to obtain 66.2 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.29(3H, s), 2.33(3H,s), 2.37(3H,s), 6.01(1H, s), 6.70(1H, d, J=8.0Hz), 6.90(1H, s), 7.07(1H, d, J=8.0Hz), 9.64(1H, brs). MS(ESI); m / z 203(M+H)+ Example 45: 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methoxyphenol a) 220.1 mg of the title compound was obtained from 176 mg of 2-amino-5-methoxyphenyl 4-methylbenzenesulfonate 2-hydroxy-4-methoxyaniline hydrochloride by the same method as in Example 44 a). ¹H-NMR (CDCl3); δ (ppm): 2.46 (3H, s), 3.62 (3H, s), 6.41 (1H, s), 6.65-6.66 (2H, m), 7.34 (2H, d, J=8.8Hz), 7.79 (2H, d, J=8.8Hz). b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methoxyphenyl 4-methylbenzenesulfonate 93.7 mg of the title compound was obtained from 220 mg of 2-amino-5-methoxyphenyl 4-methylbenzenesulfonate by the same method as in Example 44b). 1H-NMR(CDCl3);δ(ppm) 2.08(3H, s), 2.11(3H, s), 2.41(3H, s), 3.85(3H, s), 5.82(1H, s), 6.87(1H, dd, J=2.4, 8.4Hz), 7.06(1H, d, J=2.4Hz), 7.17(2H, d, J=8.4Hz), 7.20-7.24(1H, m), 7.39(2H, d, J=8.4Hz).MS(ESI); c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methoxyphenol 30.1 mg of the title compound was obtained from 93 mg of 4-methylbenzenesulfonate by the same method as in Example 44c). ¹H-NMR (CDCl3); δ (ppm) 2.27 (3H, s), 2.33 (3H, s), 3.80 (3H, s), 6.00 (1H, s), 6.45 (1H, dd, J=2.8, 8.4Hz), 6.61 (1H, d, J=2.8Hz), 7.08 (1H, d, J=8.4Hz), 9.67 (1H, brs). MS (ESI); m / z 219 (M+H)+ Example 46 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methylphenol a) 2-amino-3-methylphenyl 4-methylbenzenesulfonate 374.1 mg of the title compound was obtained from 200 mg of 2-amino-3-methylphenol by the same method as in Example 43b). 1H-NMR(CDCl3);δ(ppm) 2.14(3H, s), 2.46(3H, s), 3.79(2H,s), 6.51(1H, t, J=8.0Hz), 6.63(1H, d, J=8.0Hz), 6.91(1H, d, J=8.0Hz), 7.32(2H, d, J=8.4Hz), 7.78(2H, d, J=8.4Hz). MS(ESI); m / z 278(M+H)+ b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methylphenyl 4-methylbenzenesulfonate 269.9 mg of the title compound was obtained from 374 mg of 2-amino-3-methylphenyl 4-methylbenzenesulfonate by the same method as in Example 43c). ¹H-NMR (CDCl3); δ (ppm) 2.01 (3H, s), 2.02 (3H, s), 2.16 (3H, s), 2.43 (3H, s), 5.88 (1H, s), 7.19-7.24 (3H, m), 7.32 (2H, d, J=5.2Hz), 7.51 (2H, d, J=8.4Hz). MS (ESI); m / z 357 (M+H)+ c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methylphenol 79.2 mg of the title compound was obtained from 269 mg of 4-methylbenzenesulfonate by the same method as in Example 43d). ¹H-NMR (CD3OD); δ (ppm) 1.92 (3H, s), 2.01 (3H, s), 2.24 (3H, s), 6.02 (1H, s), 6.79 (2H, d, J=7.6Hz), 7.18 (1H, t, J=7.6Hz). MS (ESI); m / z 203 (M+H)+ Example 47 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-hydroxymethylphenol 132 mg of methyl 4-(3,5-dimethyl-1H-pyrazole-yl)-3-hydroxybenzenecarboxylate was dissolved in 2.6 ml of tetrahydrofuran, and 58 mg of lithium borohydride was added and the mixture was stirred at 50°C for 3.5 hours. 20 ml of water was added to the reaction mixture and extracted with 20 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified by preparative thin-layer silica gel column chromatography (hexane:ethyl acetate = 1:2) to obtain 12.4 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.28(3H,s), 2.44(3H, s), 4.64(2H, s), 6.02(1H, s), 6.90(1H, d, J=8.0Hz), 7.02(1H, s), 7.17(1H, d, J=8.0Hz). MS(ESI); m / z 219(M+H)+ Example 48 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylaminophenol a) 1-(2-methoxy-4-nitrophenyl)-3,5-dimethyl-1H-pyrazole 498 mg of the title compound was obtained from 700 mg of 2-methoxy-4-nitroaniline by the same method as in Example 43c). ¹H-NMR (CDCl3); δ (ppm) 2.13 (3H, s), 2.30 (3H, s), 3.93 (3H, s), 6.02 (1H, s), 7.53 (1H, d, J=8.4Hz), 7.89 (1H, d, J=2.0Hz), 7.95 (1H, dd, J=2.0, 8.4Hz). MS (ESI); m / z 248 (M+H)+ b) 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methoxyaniline 417.6 mg of the title compound was obtained from 495 mg of 1-(2-methoxy-4-nitrophenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Example 31. ¹H-NMR (CDCl3); δ (ppm) 2.06 (3H, s), 2.28 (3H, s), 3.72 (3H, s), 3.81 (2H, brs), 5.92 (1H, s), 6.28-6.31 (2H, m), 7.06 (1H, d, J=8.4Hz). MS (ESI); m / z 218 (M+H)+ c) 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methoxy-N-methylaniline 200 mg of 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methoxyaniline was dissolved in 6 ml of dimethylformamide, and 160 μl of methyl iodide and 636 mg of potassium carbonate were added and the mixture was stirred at room temperature for 2.5 hours. 50 ml of water was added to the reaction mixture and extracted with 50 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified by preparative thin-layer silica gel column chromatography (hexane:ethyl acetate = 1:3) to obtain 48.7 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.07(3H, s), 2.28(3H, s), 2.86(3H, s), 3.74(3H, s), 3.95(1H, brs), 5.92(1H, s), 6.17(1H, d, J=2.4Hz), 6.21(1H, dd, J=2.4, 8.4Hz), 7.09(1H, d, J=8.4Hz). MS(ESI); m / z 232(M+H)+ d) 25 mg of the title compound was obtained from 58.7 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylaminophenol and 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methoxy-N-methylaniline by the same method as in Example 33c). ¹H-NMR (CDCl3); δ (ppm) 2.28 (3H, s), 2.32 (3H, s), 2.83 (3H, d, J=1.2Hz), 5.98 (1H, s), 6.13-6.16 (1H, m), 6.31-6.32 (1H, m), 6.99 (1H, dd, J=1.2, 8.4Hz). MS (ESI); m / z 218 (M+H)+ Example 49 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methylphenol a) 770.1 mg of the title compound was obtained from 479 mg of 2-amino-4-methylphenyl 4-methylbenzenesulfonate 2-amino-4-methylphenol hydrochloride by the same method as in Example 43b). ¹H-NMR (CDCl3); δ (ppm) 2.21 (3H, s), 2.46 (3H, s), 3.74 (2H, brs), 6.39 (1H, d, J=8.0Hz), 6.53 (1H, s), 6.62 (1H, d, J=8.0Hz), 7.32 (2H, d, J=8.0Hz), 7.77 (2H, d, J=8.0Hz). MS (ESI); m / z 278 (M+H)+ b) 137.3 mg of the title compound was obtained from 400 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methylphenyl 4-methylbenzenesulfonate by the same method as in Example 43c). ¹H-NMR (CDCl3); δ (ppm) 2.10 (3H, s), 2.12 (3H, s), 2.35 (3H, s), 2.41 (3H, s), 5.82 (1H, s), 7.13-7.15 (3H, m), 7.20-7.22 (1H, m), 7.33-7.36 (2H, m), 7.42 (2H, d, J=8.4Hz). MS (ESI); m / z 357 (M+H)+ c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methylphenol 60.4 mg of the title compound was obtained from 167 mg of 4-methylbenzenesulfonate by the same method as in Example 43d). ¹H-NMR (CDCl3); δ (ppm) 2.29 (3H, s), 2.31 (3H, s), 2.39 (3H, s), 6.02 (1H, s), 6.97-7.02 (3H, m), 9.43 (1H, s). MS (ESI); m / z 203 (M+H)+ Example 50 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-trifluoromethylphenol a) 1-(2-methoxy-4-(trifluoromethylphenyl)-3,5-dimethyl-1H-pyrazole) 95.5 mg of the title compound was obtained from 191 mg of 2-methoxy-4-trifluoromethylaniline by the same method as in Example 43c). ¹H-NMR (CDCl3); δ (ppm) 2.05 (3H, s), 2.30 (3H, s), 3.86 (3H, s), 5.99 (1H, s), 7.22 (1H, s), 7.31 (1H, d, J=8.0Hz), 7.46 (1H, d, J=8.0Hz). MS (ESI); m / z 271 (M+H)+ b) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-trifluoromethylphenol 25.7 mg of the title compound was obtained from 95.5 mg of 1-(2-methoxy-4-trifluoromethylphenyl)-3,5-dimethyl-1H-pyrazole by the same method as in Example 33c). ¹H-NMR (CDCl3); δ (ppm) 2.31 (3H, s), 2.45 (3H, s), 6.08 (1H, s), 7.15-7.18 (1H, m), 7.30-7.35 (2H, m), 10.64 (1H, s). MS (ESI); m / z 257 (M+H)+ Example 51 2-(3,5-dimethyl-1H-pyrazole-1-yl)-6-methylphenol a) 159.9 mg of the title compound was obtained from 200 mg of 2-amino-6-methylphenyl 4-methylbenzenesulfonate 6-amino-o-cresol hydrochloride by the same method as in Example 43b). ¹H-NMR (CDCl3); δ (ppm) 2.06 (3H, s), 2.48 (3H, s), 3.96 (2H, s), 6.53-6.55 (1H, m), 6.59-6.61 (1H, m), 6.93 (1H, t, J=7.6Hz), 7.37 (2H, d, J=8.0Hz), 7.90 (2H, d, J=8.0Hz). MS (ESI); m / z 278 (M+H)+ b) 48.8 mg of the title compound was obtained from 159.5 mg of 2-(3,5-dimethyl-1H-pyrazole-1-yl)-6-methylphenyl 4-methylbenzenesulfonate by the same method as in Example 43c). ¹H-NMR (CDCl3); δ (ppm) 2.09 (3H, s), 2.10 (3H, s), 2.43 (3H, s), 2.49 (3H, s), 5.67 (1H, s), 7.13-7.32 (5H, m), 7.48 (2H, d, J=8.0Hz). MS (ESI); m / z 357 (M+H)+ c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-6-methylphenol 12 mg of the title compound was obtained from 48.5 mg of 4-methylbenzenesulfonate by the same method as in Example 43d). ¹H-NMR (CDCl3); δ (ppm) 2.30 (3H, s), 2.31 (3H, s), 2.38 (3H, s), 6.03 (1H, s), 6.81 (1H, t, J=8.0Hz), 7.03-7.09 (2H, m), 9.79 (1H, s). MS (ESI); m / z 203 (M+H)+ Example 52 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-ethylphenol a) 4-chloro-5-ethyl-2-nitrophenyl methanesulfonate 150 mg of 4-chloro-5-ethyl-2-nitrophenol was dissolved in 1.5 ml of dichloromethane, and 156 μl of triethylamine and 69 μl of methanesulfonyl chloride were added and the mixture was stirred at room temperature for 30 minutes. 50 ml of water was added to the reaction mixture and extracted with 60 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure to obtain 200.7 mg of the title compound. ¹H-NMR (CDCl3); δ (ppm) 1.28 (3H, t, J=7.6 Hz), 2.83 (2H, q, J=7.6 Hz), 3.37 (3H, s), 7.42 (1H, s), 8.09 (1H, s). b) 2-amino-5-ethylphenyl methanesulfonate 200 mg of 4-chloro-5-ethyl-2-nitrophenyl methanesulfonate was dissolved in 4 ml of ethanol, and 200 mg of 10% palladium / carbon was added. The mixture was stirred at room temperature under a hydrogen atmosphere for 4 hours. After filtering out the insoluble matter, the solvent was removed under reduced pressure to obtain 74.9 mg of the title compound. ¹H-NMR (CD3OD); δ (ppm) 1.26 (3H, t, J=7.6Hz), 2.73 (2H, q, J=7.6Hz), 3.47 (3H, s), 7.28-7.46 (3H, m). MS (ESI); m / z 216 (M+H)+ c) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-ethylphenyl methanesulfonate 28.1 mg of the title compound was obtained from 74.5 mg of 2-amino-5-ethylphenyl methanesulfonate by the same method as in Example 43c). ¹H-NMR (CDCl3); δ (ppm) 1.28 (3H, t, J=7.6Hz), 2.17 (3H, s), 2.26 (3H, s), 2.65 (3H, s), 2.73 (2H, q, J=7.6Hz), 6.00 (1H, s), 7.24-7.26 (1H, m), 7.33-7.37 (2H, m). MS (ESI); m / z 295 (M+H)+ d) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-ethylphenol 28 mg of methanesulfonate was dissolved in 0.1 ml of methanol, and 0.07 ml of 5N hydrochloric acid was added and heated under reflux for 30 minutes. 15 ml of water was added to the reaction mixture and extracted with 15 ml of ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure. The compound was purified using preparative thin-layer silica gel column chromatography (hexane:ethyl acetate = 4:1) to obtain 7.4 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 1.24(3H, t, J=7.6Hz), 2.29(3H, s), 2.38(3H, s), 2.63(2H, q, J=7.6Hz), 6.02(1H, s), 6.73-6.75(1H, m), 6.94(1H, s), 7.10(1H, d, J=8.0Hz), 9.67(1H, s). MS(ESI); m / z 217(M+H)+ Example 53 2-(4-fluoro-3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 1-(2-benzyloxyphenyl)-4-fluoro-3,5-dimethyl-1H-pyrazole 500 mg of 2-benzyloxyphenylhydrazine hydrochloride and 251 mg of 3-fluoropentan-2,4-dione were added to 12 ml of ethanol and heated under reflux for 1.5 hours. The reaction mixture was concentrated under reduced pressure and purified using silica gel column chromatography (hexane:ethyl acetate = 6:1 to 5:1) to obtain 417 mg of the title compound. ¹H-NMR (CDCl3); δ (ppm) 2.07 (3H, s), 2.30 (3H, s), 5.04 (2H, s), 7.03-7.07 (2H, m), 7.24-7.37 (7H, m). MS (ESI); m / z 297 (M+H)+ b) 416 mg of 2-(4-fluoro-3,5-dimethyl-1H-pyrazole-1-yl)phenol 1-(2-benzyloxyphenyl)-4-fluoro-3,5-dimethyl-1H-pyrazole was dissolved in 16 ml of methanol, 42.6 mg of 10% palladium / carbon was added, and the mixture was stirred at room temperature under a hydrogen atmosphere for 24 hours. After filtering out the insoluble matter, the filtrate was removed under reduced pressure, and the resulting residue was purified using silica gel column chromatography (hexane:ethyl acetate = 5:1) to obtain 290 mg of the title compound. 1H-NMR(CDCl3);δ(ppm) 2.28(3H, s), 2.33(3H, s), 6.90(1H, t, J=8.0Hz), 7.06(1H, d, J=8.0Hz), 7.15(1H, d, J=8.0Hz), 7.19(1H, t, J=8.0Hz). MS(ESI); m / z 207(M+H)+ Example 54 5-bromo-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol a) 5-bromo-2-hydrazinylphenol 4-methylbenzenesulfonate 1.0 g of 2-amino-5-bromophenol was suspended in 7 ml of ethanol, and 1.5 ml of concentrated hydrochloric acid was added dropwise at -10°C. Then, 636 mg of tert-butyl nitrite was added dropwise at the same temperature, and the mixture was stirred at the same temperature for 1 hour to obtain a diazonium salt solution. In another flask, 2.49 g of stannous chloride dihydrate, 1.08 g of p-toluenesulfonic acid monohydrate, and 15 ml of ethanol were added, and the mixture was stirred at -10°C for 15 minutes. To this solution, the previously prepared diazonium salt solution was added dropwise at -10°C, and the mixture was stirred at the same temperature for 1 hour. 30 ml of tert-butyl methyl ether was added, and after stirring for 15 minutes, the resulting precipitate was filtered to obtain 0.9 g of the title compound. b) 5-bromo-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 5-bromo-2-hydrazinylphenol 0.9 g of 4-methylbenzenesulfonate and 0.8 g of acetylacetone were added to 25 ml of ethanol and heated under reflux for 1 hour. After cooling to room temperature, the mixture was concentrated under reduced pressure and the resulting residue was dissolved in 50 ml of ethyl acetate and washed twice with 20 ml of saturated sodium bicarbonate solution. The organic layer was dehydrated with anhydrous sodium sulfate, and the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (hexane:ethyl acetate = 4:1) to obtain 650 mg of the title compound. 1H-NMR(CDCl3); δ(ppm) 2.30(3H, s), 2.40(3H, s), 6.05(1H, s), 7.01-7.08(2H, m), 7.26(1H, s). MS(ESI); m / z 267(M+H)+ Example 55 5-bromo-2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol 558 mg of the title compound was obtained from 0.9 g of 4-methylbenzenesulfonate and 1.07 g of 3-chloropentan-2,4-dione, prepared in the same manner as in Example 54a), by the same method as in Example 54b). ¹H-NMR (CDCl3); δ (ppm) 2.30 (3H, s), 2.38 (3H, s), 7.02-7.08 (2H, m), 7.27 (1H, d, J=2.0Hz), 9.62 (1H, s). MS (ESI); m / z 303 (M+H)+ Example 56 5-bromo-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 320 mg of the title compound was obtained from 0.9 g of 4-methylbenzenesulfonate and 0.9 g of 3-methylpentan-2,4-dione, prepared in the same manner as in Example 54a), by the same method as in Example 54b). ¹H-NMR (CDCl3); δ (ppm) 1.98 (3H, s), 2.24 (3H, s), 2.31 (3H, s), 7.00-7.06 (2H, m), 7.25 (1H, d, J=1.6 Hz)), 10.34 (1H, s). MS (ESI); m / z 281 (M+H)+ Example 57 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate a) 4-nitro-1,3-phenylene diacetate Under a nitrogen atmosphere, 5.0 g of 4-nitrobenzene-1,3-diol was dissolved in 50 ml of methylene chloride, and under ice cooling, 5.35 g of pyridine, 0.39 g of 4-dimethylaminopyridine, and 8.12 g of acetic anhydride were added sequentially. The mixture was heated to room temperature and stirred for 1 hour. The reaction mixture was sequentially washed with 50 ml of water, 100 ml of 1N hydrochloric acid, 100 ml of saturated sodium bicarbonate solution, and 100 ml of saturated saline solution, dehydrated with anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 7.4 g of the title compound. ¹H-NMR (CDCl3); δ (ppm) 2.33 (3H, s), 2.37 (3H, s), 7.09 (1H, d, J=2.4 Hz), 7.18 (1H, dd, J=2.4, 9.2 Hz), 8.16 (1H, d, J=9.2 Hz). b) 3-Hydroxy-4-nitrophenyl acetate Under a nitrogen atmosphere, 1.0 g of 4-nitro-1,3-phenylene diacetate was dissolved in 25 ml of chloroform, and 2.23 g of aluminum chloride was added under ice cooling. The mixture was heated to room temperature and stirred for 3 hours. 100 ml of water was added, and the mixture was extracted three times with 30 ml of methylene chloride. The organic layers were combined and washed sequentially with 25 ml of 1N hydrochloric acid and 25 ml of saturated saline solution, dehydrated with anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 20:1) to obtain 610 mg of the title compound. ¹H-NMR (CDCl3):δ (ppm) 2.32 (3H, s), 6.77 (1H, dd, J=2.4 Hz, J=9.2 Hz), 6.95 (1H, d, J=2.4 Hz), 8.14 (1H, d, J=9.2 Hz), 10.70 (1H, s). MS (ESI); m / z 196 (MH) - c) 4-amino-3-hydroxyphenyl acetate 3.0 g of 3-hydroxy-4-nitrophenyl acetate was dissolved in 50 ml of ethyl acetate, 300 mg of 10% palladium / carbon was added, and the mixture was stirred at room temperature under a hydrogen atmosphere for 10 hours. After filtering out the insoluble matter, the filtrate was removed under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 1:1) to obtain 2.48 g of the title compound.¹H-NMR (DMSO-d6); δ (ppm) 2.17 (3H, s), 4.45 (2H, brs), 6.28 (1H, dd, J=2.4, 8.4Hz), 6.40 (1H, d, J=2.4Hz), 6.53 (1H, d, J=8.4Hz), 9.26 (1H, brs). MS (ESI); m / z 167 (M+) d) 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate 4-hydrazinyl-3-hydroxyphenyl acetate prepared in the same manner as in Example 54a) using 1.0 g of 4-amino-3-hydroxyphenyl acetate 330 mg of the title compound was obtained from 0.9 g of 4-methylbenzenesulfonate and 0.9 g of acetylacetone by the same method as in Example 54b). ¹H-NMR (CDCl3); δ (ppm) 2.29 (3H, s), 2.30 (3H, s), 2.41 (3H, s), 6.04 (1H, s), 6.68 (1H, dd, J=2.4, 8.8 Hz), 6.85 (1H, d, J=2.4 Hz), 7.19 (1H, d, J=8.8 Hz), 10.14 (1H, s). MS (ESI); m / z 247 (M+H)+. Example 58 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate 30 mg of the title compound was obtained from 0.9 g of 4-methylbenzenesulfonate and 1.2 g of 3-chloropentan-2,4-dione, using 1.0 g of 4-amino-3-hydroxyphenyl acetate prepared in the same manner as in Example 54a), using the same method as in Example 54b). 1H-NMR(CDCl3); δ(ppm) 2.30(3H, s), 2.31(3H, s), 2.39(3H, s), 6.70(1H, dd, J=2.8, 8.8Hz), 6.86(1H, d, J=2.8Hz), 7.17(1H, d, J=8.8 Hz), 9.50(1H, s). MS(ESI); m / z 281(M+H)+ Example 59 3-Hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenyl acetate 230 mg of the title compound was obtained from 0.6 g of 4-methylbenzenesulfonate and 1.0 g of 3-methylpentan-2,4-dione, using 1.0 g of 4-amino-3-hydroxyphenyl acetate prepared in the same manner as in Example 54a), in the same manner as in Example 54b). 1H-NMR(CDCl3); δ(ppm) 1.99(3H, s), 2.24(3H, s), 2.30(3H, s), 2.32(3H, s), 6.66(1H, dd, J=2.8, 8.4Hz), 6.83(1H, d, J=2.8Hz), 7.17(1H, d, J=8.4 Hz), 10.22(1H, s). MS(ESI); m / z 261(M+H)+ Example 60 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methoxy-5-methylphenol a) 1,4-dimethoxy-2-methyl-5-nitrobenzene 6.0 g of 2,5-dimethoxytoluene was dissolved in 20 ml of acetic acid, and 4.32 g of fuming nitric acid (d=1.50) in 10 ml of acetic acid solution was added dropwise over 5 minutes at 40°C. The mixture was stirred at the same temperature for 30 minutes, cooled to room temperature, and stirred for another 30 minutes. The reaction mixture was diluted with 300 ml of cold water, the precipitate was filtered off and washed with 100 ml of cold water. The mixture was dried under reduced pressure to obtain 7.5 g of the title compound. ¹H-NMR (CDCl3); δ (ppm) 2.28 (3H, s), 3.84 (3H, s), 3.92 (3H, s), 6.90 (1H, s), 7.40 (1H, s). MS (ESI); m / z 198 (M+H)+ b) 4-Methoxy-5-methyl-2-nitrophenol A 30 ml solution of 6.0 g of 1,4-dimethoxy-2-methyl-5-nitrobenzene in methylene chloride was cooled to -20°C, and 30 ml of a 1 M boron trichloride solution in methylene chloride was added dropwise at the same temperature. After raising the temperature to room temperature, the mixture was stirred for 16 hours, and the reaction mixture was added to 50 ml of saturated sodium bicarbonate solution. The mixture was extracted three times with 100 ml of ethyl acetate. The organic layers were combined, washed with 100 ml of water and 50 ml of saturated brine, dehydrated with anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 9:1) to obtain 4.25 g of the title compound. ¹H-NMR (CDCl3); δ (ppm) 2.26 (3H, s), 3.84 (3H, s), 6.94 (1H, s), 7.39 (1H, s), 10.46 (1H, s). MS (ESI); m / z 182 (MH)- c) 4-Methoxy-5-methyl-2-nitrophenyl 4-methylbenzenesulfonate Under a nitrogen atmosphere, 9.15 g of p-toluenesulfonyl chloride was added to 8.0 g of 4-methoxy-5-methyl-2-nitrophenol in 80 ml of methylene chloride solution and cooled to 0°C. 4.86 g of triethylamine was added and the mixture was stirred for 2 hours. The reaction mixture was poured into 150 ml of water and extracted with 150 ml of methylene chloride. The organic layer was washed with 100 ml of water and 50 ml of saturated saline solution, dehydrated with anhydrous sodium sulfate, and then concentrated under reduced pressure.The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 9:1) to obtain 12.0 g of the title compound. ¹H-NMR (CDCl3); δ (ppm) 2.26 (3H, s), 2.46 (3H, s), 3.87 (3H, s), 7.19 (1H, s), 7.33 (1H, s), 7.34 (2H, d, J=8.4Hz), 7.77 (2H, d, J=8.4Hz). MS (ESI); m / z 336 (MH)- d) 2-amino-4-methoxy-5-methylphenyl 4-methylbenzenesulfonate 3.2 g of the title compound was obtained using 4.0 g of 4-methoxy-5-methyl-2-nitrophenyl 4-methylbenzenesulfonate in the same manner as in Example 57c). ¹H-NMR (DMSO-d6); δ (ppm) 1.91 (3H, s), 2.41 (3H, s), 3.64 (3H, s), 4.73 (2H, brs), 6.25 (1H, s), 6.64 (1H, s), 7.43 (2H, d, J=8.4Hz), 7.79 (2H, d, J=8.4Hz). MS (ESI); m / z 308 (M+H)+ e) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methoxy-5-methylphenyl 4-methylbenzenesulfonate Using 1.0 g of 2-amino-4-methoxy-5-methylphenyl 4-methylbenzenesulfonate, 400 mg of the title compound was obtained in the same manner as in Examples 54a) and 54b). ¹H-NMR (CDCl3); δ (ppm) 2.10 (6H, s), 2.25 (3H, s), 2.41 (3H, s), 3.79 (3H, s), 5.80 (1H, s), 6.71 (1H, s), 7.15 (2H, d, J=8.4Hz), 7.27 (1H, s), 7.35 (2H, d, J=8.4Hz). MS (ESI); m / z 387 (M+H)+ f) 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methoxy-5-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methoxy-5-methylphenyl 70 mg of the title compound was obtained using 200 mg of 4-methylbenzenesulfonate in the same manner as in Example 29.1H-NMR(CDCl3); δ(ppm) 2.21(3H, s), 2.29(3H, s), 2.39(3H, s), 3.78(3H, s), 6.02(1H, s), 6.67(1H, s), 6.89(1H, s), 8.87(1H, s). MS(ESI); m / z 233(M+H)+. Example 61 4-Chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol a) 2-amino-4-chloro-5-methylphenol 5.0 g of 4-chloro-5-methyl-2-nitrophenol was added to 100 ml of methanol to a solution of 8.71 g of zinc powder activated with hydrochloric acid and 7.1 g of ammonium chloride in 20 ml of water at 0°C. This suspension was stirred at room temperature for 4 hours, and the insoluble matter was filtered using Celite and washed with 100 ml of ethyl acetate. The filtrate and washings were combined and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane:ethyl acetate = 3:2) to obtain 1.4 g of the title compound. ¹H-NMR (DMSO-d6); δ (ppm) 2.10 (3H, s), 4.57 (2H, brs), 6.54 (1H, s), 6.58 (1H, s), 9.11 (1H, s). MS (ESI); m / z 157 (M)+ b) 4-chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol 120 mg of the title compound was obtained using 1.0 g of 2-amino-4-chloro-5-methylphenol in the same manner as in Examples 54a) and 54b). 1H-NMR(CDCl3); δ(ppm) 2.29(3H, s), 2.34(3H, s), 2.41(3H, s), 6.03(1H, s), 6.96(1H, s), 7.19(1H, s), 9.88(1H, s). MS(ESI); m / z 237(M+H)+ Example 62 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4,5-dimethylphenol 630 mg of the title compound was obtained using 1.0 g of 2-amino-4,5-dimethylphenol in the same manner as in Examples 54a) and 54b). ¹H-NMR (CDCl3); δ (ppm) 2.21 (3H, s), 2.24 (3H, s), 2.29 (3H, s), 2.38 (3H, s), 6.00 (1H, s), 6.88 (1H, s), 6.94 (1H, s), 9.28 (1H, s). MS (ESI); m / z 217 (M+H)+ Example 63: 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol. In Example 58, 200 mg of the title compound was obtained as a byproduct during silica gel column chromatography purification. ¹H-NMR (CD3OD); δ (ppm) 2.07 (3H, s), 2.20 (3H, s), 6.36 (1H, dd, J=2.4, 8.4Hz), 6.42 (1H, d, J=2.4Hz), 6.98 (1H, d, J=8.4Hz). MS (ESI); m / z 239 (M+H)+ Test Example 1: Measurement of Antifungal Activity The antifungal activity was measured using the following method. The evaluation compound was dissolved in dimethyl sulfoxide (DMSO) before use. The test medium used was RPMI1640 medium containing 0.165 M 3-morpholinopropanesulfonic acid (MOPS). Trichophyton mentagrophytes (ATCC18748) or Trichophyton rubrum (ATCC10218) were used as test bacteria. 100 μl of the test bacterial species was dispensed at a concentration of 1 × 10⁴ conidia / ml, mixed with the evaluation compound on a 96-well half-area plate to a DMSO concentration of 1%, and cultured at a culture temperature of 28°C for 3 days (Trichophyton mentagrophytes) or 4 days (Trichophyton rubrum). Subsequently, 5 μl of Cell Counting Kit 8 (WST8) was added, and the absorbance at 450 nm and 595 nm was measured and used as the background value. Then, the cultures were incubated at 28°C for 5 hours (Trichophyton mentagrophytes) or overnight (Trichophyton rubrum) to allow color development, and the absorbance at 450 nm and 595 nm was measured again. The growth inhibition rate was calculated from the difference with the background value, and the MIC value (μg / ml) was defined as the 80% growth inhibition concentration. Test Example 2: Nail Permeability Test The example compounds and comparative compounds (amorolfine hydrochloride, terbinafine hydrochloride, cyclopirox) were dissolved at a concentration of 10 mg / ml in a solution of ethyl acetate:propylene glycol (1:1) or dimethyl sulfoxide. 2 μl of each solution was added to a bovine nail slice (approximately 100 μm thick) placed on low-melting-point agarose. After standing in a 28°C incubator for 5 days, the low-melting-point agarose was collected and dissolved by heating with distilled water. The drug concentration in the solution was quantified using high-performance liquid chromatography / mass spectrometry to determine the amount of drug that permeated the nail, and the permeability was calculated. The results confirmed that the example compounds exhibited significantly higher nail permeability compared to amorolfine hydrochloride and terbinafine hydrochloride. As mentioned above, there is a strong need for the development of a compound that not only has antifungal activity but also high permeability to the nail as a topical treatment for onychomycosis. The inventors of this invention have been able to provide an antifungal agent containing a compound represented by formula (I) or a salt thereof as an active ingredient, which has strong antifungal activity and high nail permeability. Furthermore, this invention can be used as a topical drug, and the drug interactions, liver damage, and side effects from long-term administration that are problematic with approved oral antifungal agents can be overcome by using this topical drug, making it possible to administer medication to patients infected with dermatophytes that cannot be administered orally.
Claims
A compound represented by the following formula (I), or a salt thereof. (wherein R1 represents a hydrogen atom, C1-6 alkyl, or trifluoromethyl; R2 represents a hydrogen atom, C1-6 alkyl, halogen, -COO(C1-6 alkyl), or -(CH2)1-3COOR (where R represents a hydrogen atom or C1-6 alkyl); R3 represents a hydrogen atom, C1-6 alkyl, amino, trifluoromethyl, or -OR (where R represents a hydrogen atom or C1-6 alkyl); R4 represents a hydroxyl group; R5 represents a hydrogen atom, C1-6 alkyl, hydroxyl group, or halogen; R6 represents a C1-6 alkyl group, trifluoromethyl group, halogen, amino group, -NRaRb, nitro group, hydroxy C1-6 alkyl group, -CONRaRb, -COO(C1-6 alkyl group), -COOH group, -(CH2)1-3COOR group, -ORa group (where R is a hydrogen atom or a C1-6 alkyl group, and Ra and Rb may be the same or different, representing a hydrogen atom, a C1-6 alkyl group, or a C1-6 acyl group). R7 represents a hydrogen atom, a C1-6 alkyl group, -OR group (where R is a hydrogen atom or a C1-6 alkyl group), or halogen group. R8 represents a hydrogen atom, a C1-6 alkyl group, a hydroxyl group, amino group, or nitro group. However, if R1 is a hydrogen atom, R3 is excluded from the hydrogen atom, and compounds where R1 is a tert-butyl group, R3 is an amino group, R4 is a hydroxyl group, and R6 is a methyl group are excluded. The compound or salt thereof according to claim 1, wherein R1 represents C1-6 alkyl, trifluoromethyl, and R3 represents C1-6 alkyl, trifluoromethyl, -OR (where R represents a hydrogen atom or C1-6 alkyl). The compound or salt thereof according to claim 1, wherein R1 represents a C1-6 alkyl group and R3 represents a C1-6 alkyl group. The compound or salt thereof according to claim 1, wherein R1 represents a C1-4 alkyl group, R2 represents a hydrogen atom, a C1-4 alkyl group, or a halogen, R3 represents a C1-4 alkyl group, R4 represents a hydroxyl group, R5 represents a hydrogen atom, R6 represents a C1-4 alkyl group, trifluoromethyl group, halogen, amino, -NRaRb, nitro, hydroxy C1-4 alkyl group, -CONRaRb, -COO(C1-4 alkyl group), -COOH, -(CH2)1-3COOR, -ORa (where R is a hydrogen atom or a C1-4 alkyl group, and Ra and Rb may be the same or different, representing a hydrogen atom, a C1-4 alkyl group, or a C1-4 acyl group), R7 represents a hydrogen atom, and R8 represents a hydrogen atom, a C1-4 alkyl group, a hydroxyl group, amino, or nitro. The compound or salt thereof according to claim 1, wherein R1 represents methyl, R2 represents a hydrogen atom, methyl, or halogen, R3 represents methyl, R4 represents a hydroxyl group, R5 represents a hydrogen atom, R6 represents a C1-3 alkyl, trifluoromethyl, halogen, amino, -NRaRb, nitro, hydroxy C1-3 alkyl, -CONRaRb, -COO(C1-3 alkyl), -COOH, -(CH2)1-3COOR, -ORa (where R is a hydrogen atom or a C1-3 alkyl, and Ra and Rb may be the same or different, representing a hydrogen atom, a C1-3 alkyl, or a C1-3 acyl), R7 represents a hydrogen atom, and R8 represents a hydrogen atom. 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-fluorophenol 2-(5-hydroxy-3-methyl-1H-pyrazole-1-yl)phenol 2-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)phenol 2-(3,5-bistrifluoromethyl)-1H-pyrazole-1-yl)phenol 2-(3-methyl-1H-pyrazole-1-yl)phenol 2-(5-methyl-1H-pyrazole-1-yl)phenol 2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 2-(5-amino-3-tert-butyl-1H-pyrazole-1-yl)phenol 4-chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-chloro-6-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(3,5-diethyl-1H-pyrazole-1-yl)phenol 3-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,2-diol 2-(4-ethyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol 5-fluoro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 4-fluoro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol 1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-carboxylate ethyl 3-(1-(2-hydroxyphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propanoate methyl 2-(4-butyl-3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-fluorophenol 5-chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-nitrophenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-nitrophenol 3-(1-(2-hydroqiphenyl)-3,5-dimethyl-1H-pyrazole-4-yl)propionic acid 5-chloro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 5-amino-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 5-nitro-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 4-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol 5-amino-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylate methyl 3-amino-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzenecarboxylate 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxy-N,N-dimethylbenzamide 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzamide 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzenecarboxylic acid 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)benzamide 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxybenzamide 2-(3,5-dimethyl-1H-pyrazole-1-yl)benzene-1,3-diol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methoxyphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-3-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-hydroxymethylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylaminophenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-trifluoromethylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-6-methylphenol 2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-ethylphenol, 2-(4-fluoro-3,5-dimethyl-1H-pyrazole-1-yl)phenol, 5-bromo-2-(3,5-dimethyl-1H-pyrazole-1-yl)phenol, 5-bromo-2-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)phenol, 5-bromo-2-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenol, 4-(3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate, 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-3-hydroxyphenyl acetate, 3-hydroxy-4-(3,4,5-trimethyl-1H-pyrazole-1-yl)phenyl acetate, 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4-methoxy-5-methylphenol, 4-chloro-2-(3,5-dimethyl-1H-pyrazole-1-yl)-5-methylphenol, Compounds or salts thereof that are 2-(3,5-dimethyl-1H-pyrazole-1-yl)-4,5-dimethylphenol, or 4-(4-chloro-3,5-dimethyl-1H-pyrazole-1-yl)-benzene-1,3-diol. An antifungal agent characterized by containing a compound represented by the following formula (II), or a salt thereof. (wherein R9 represents a hydrogen atom, C1-6 alkyl, or trifluoromethyl; R10 represents a hydrogen atom, C1-6 alkyl, halogen, -COO(C1-6 alkyl), or -(CH2)1-3COOR (where R represents a hydrogen atom or C1-6 alkyl); R11 represents a hydrogen atom, C1-6 alkyl, amino, trifluoromethyl, or -OR (where R represents a hydrogen atom or C1-6 alkyl); R12 represents a hydroxyl group; R13 represents a hydrogen atom, C1-6 alkyl, hydroxyl group, or halogen; R14 represents a hydrogen atom, C1-6 alkyl group, trifluoromethyl group, halogen, amino, -NRaRb, nitro, hydroxy C1-6 alkyl group, -CONRaRb, -COO(C1-6 alkyl group), -COOH, -(CH2)1-3COOR, -ORa (where R represents a hydrogen atom or C1-6 alkyl group, and Ra and Rb may be the same or different, representing a hydrogen atom, C1-6 alkyl group, or C1-6 acyl group). R15 represents a hydrogen atom, C1-6 alkyl group, -OR (where R represents a hydrogen atom or C1-6 alkyl group), halogen, and R16 represents a hydrogen atom, C1-6 alkyl group, hydroxyl group, amino, or nitro group. An anti-onychomycotic agent characterized by containing the compound or a salt thereof described in claim 1, claim 6, or claim 7. The antifungal agent according to claim 7, which is a topical preparation. An anti-onychomycotic agent according to claim 8 or 9, which is a topical preparation.
